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PURPOSE OF STUDY
  Oral drug delivery has been known for decades as the most widely utilized route 
of administration among all the routes that have been explored for the systemic delivery 
of drugs via various pharmaceutical products of different dosage forms1. The chain of 
events that occur following administration of a solid dosage form such as a tablet or a 
capsule until its absorption into systemic circulation are depicted in below.
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Fig1. Schematic representation of steps involved in the absorption of 
solid dosage forms
Solid  drugs  administered  orally  for  systemic  activity  must  dissolve  in  the 
gastrointestinal  fluids  prior  to  their  absorption.  Unless  the  drug goes  into  solution,  it 
cannot be absorbed into systemic circulation. 
Rate Determining Step (RDS): 2
In  a  series  of  kinetic  or  rate  process,  the  rate  at  which  the  drug  reaches  the 
systemic circulation is determined by the slowest of the various steps involved in the 
sequence. Such a step is called as the rate determining or rate limiting step.
Absolute or intrinsic solubility: 2  
It is defined as the maximum amount of solute dissolved in a given solvent under 
standard conditions of temperature, pressure and pH. It is a static property.
Dissolution rate: 2
It is defined as the amount of solid substances that goes into solution per unit time 
under standard conditions of temperature, pH and solvent composition and constant solid 
surface. It is a dynamic process.
Several drugs have poor aqueous solubility to have a bearing on dissolution rate. 
The matter is of great concern when the solubility is less than 1-2 mg /mL in the pH range 
of 2-8.
The solubility behavior of drugs remains one of the most challenging aspects in 
formulation  development.  With  the  advent  of  combinatorial  chemistry  and  high 
throughput  screening,  the  number  of  poorly  soluble  compounds  has  dramatically 
increased3. The dissolution rate of drug from its dosage form is now considered as an 
important  parameter  in  the  absorption.  Dissolution  is  the  rate  limiting  step  in  the 
absorption of drugs from solid dosage form especially when the drug is poorly soluble. 
Thus the rate of dissolution of drugs in gastrointestinal fluids could influence the 
rate and extent of their absorption. In as much as the rate of dissolution of solid is a  
function  of  particle  size  and  its  solubility  in  the  dissolution  medium.4An  important 
prerequisite for the absorption of a drug by all mechanisms except endocytosis is that it 
must  be  present  in  aqueous  solution.  This  in  turn  depends  on  the  drug’s  aqueous 
solubility and its dissolution rate.
Effect of particle size reduction:
The stability characteristics of the drug may be altered considerably by reduction 
of particle size. The resultant increase in surface area places more of the drug molecules 
in a vulnerable position for rapid degradation by the gastro-intestinal fluids5.
Particle  size  reduction  is  usually  achieved  by  1.conventional  trituration  and 
grinding 2.Ball milling 3.Fluid energy micronization 4.controlled precipitation by change 
of  solvents  or  temperature,  application  of  ultrasonic  waves6-8 and  spray  drying 
5.administration of liquid solution form which upon dissolution with gastric fluids, and 
the dissolved drug may precipitate  in very fine particles9.  6.  Administration  of  water 
soluble salts  of poorly soluble compounds from which from which the parent neutral 
forms may precipitate in ultra fine from in gastro intestinal fluids.
Although the reduction of particle size can be easily and directly accomplished by 
the first four methods (1-4), the resultant fine particles may not produce expected faster 
dissolution  and  absorption.  This  primarily  results  from the  possible  aggregation  and 
agglomeration of the fine particles due to their and agglomeration of the fine particles due 
to their increased surface energy and the subsequent stronger Vander Wall’s attraction 
between non polar molecules. This was demonstrated by Lin et al10. Who showed that the 
invitro dissolution rates of micronized griseofulvin and glutethimide were slower than 
those of their coarser particles. Further more, drugs with plastic properties are difficult to 
subdivide  by methods  1-3.  They have  more  tendencies  to  stick together  even if  fine 
powders can be produced by controlled precipitation.
The main perspective of the present study aims at overcoming these problems by 
solid dispersion technology by using carriers like PVP-10, PVP-40, PVP-360 and PVA-
8136.With a view to develop fast release formulation of aceclofenac and hence improve 
its  dissolution  characteristics.  Aceclofenac  is  an  effective  NSAID’s  is  practically 
insoluble in water. Where the dissolution is rate limiting.
The research work envisaged was 
1. Literature survey on solid dispersion methods and carriers for solid dispersion.
2. Preparation, characterization and evaluation of solid dispersions of aceclofenac with 
PVP and PVA.
INTRODUCTION
When the drug is administered in a solid dosage form such as tablet, capsule, or 
suspension it must be released from the dosage form and dissolved in the gastrointestinal 
fluids before it  can be absorbed. The bioavailability  of poorly water  soluble drugs is 
limited by their dissolution rates, which are in turn controlled by the surface area that 
they are present  for  dissolution.  If  the rate  of  dissolution  of  the drug is  significantly 
slower than the rate of absorption, the dissolution of the drug becomes the rate limiting 
step in the absorption process, and the particle size of the drug is of great importance in 
the transport from the gastrointestinal tract to the site of action11.  
Consideration of the modified Noyes-Whitney equation12,13  provides some hints 
as to how the dissolution rate of even very poorly soluble compounds might be improved 
to minimize the limitations to oral availability: 
where dC/dt is the rate of dissolution, “A” is the surface are available for dissolution, “D” 
is the diffusion coefficient of the compound, “Cs” is the solubility of the compound in the 
dissolution medium, “C” is the concentration of drug in the medium at time t and h is the 
thickness  of  the  diffusion  boundary  layer  adjacent  to  the  surface  of  the  dissolving 
compound. The main possibilities for improving dissolution according to this analysis are 
to increase the surface area available for dissolution by decreasing the particle size of the 
solid  compound  and/or  by  optimizing  the  wetting  characteristics  of  the  compound 
surface,  to  decrease  the  boundary  layer  thickness,  to  ensure  sink  conditions  for 
dissolution and, last but definitely not least, to improve the apparent solubility of the drug 
under physiologically relevant conditions.
Of these possibilities, changes in the hydrodynamics are difficult to invoke in vivo 
and  the  maintenance  of  sink  conditions  will  depend  on  how  permeable  the 
gastrointestinal mucosa is to the compound as well as on the composition and volume of 
the lumenal fluids. Although some research effort has been directed towards permeability 
enhancement  using  appropriate  excipients,  results  to  date  have  not  been  particularly 
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encouraging. Administration of the drug in the fed state may be an option to improve the 
dissolution  rate  and  also  to  increase  the  time  available  for  dissolution;  the  likely 
magnitude  of  the  food  effect  can  be  forecasted  from dissolution  tests  in  biorelevant 
media14.  However,  the  most  attractive  option  for  increasing  the  release  rate  is 
improvement of the solubility through formulation approaches.
DEFINITION:
 Solid dispersion is defined as the dispersion of one or more active ingredients in 
an inert carrier or matrix at solid state prepared by the melting (fusion), solvent or the 
melting-solvent method.
The dispersion of  a  drug or  drugs  in  a  solid  diluent  or  diluents  by traditional 
mechanical  mixing  is  not  included  in  this  category.  The  term  coprecipitate (more 
accurately coevaporate) has also been frequently used when a solid dispersion is prepared 
by a solvent method.
ADVANTAGES OF SOLID DISPERSIONS:
 Solid dispersion of drugs in solid state is helpful in stabilizing unstable drugs.
 The  PEGs  may  protect  certain  drug  e.g.  cardiac  glycosides  against  the 
decomposition by saliva and allow buccal absorption.
  Solid  dispersions  may  be  thermodynamically  more  active  form of  drug  and 
directly influence the diffusion and release rate.
  An  increased  diffusion  of  steroid  from the  ointment  was  obtained.e.g.  solid 
dispersion of prednisolone urea dispersion.
  Solid dispersion technology can be used to solidify liquid drugs.e.g. clofibrate 
and benzyl benzoate.
DISADVANTAGES OF SOLID DISPERSIONS:
 Tackiness and decommission during preparation and formulation.
 The  oral  administration  of  solid  dispersions  without  concomitant  reduction  in 
dose  may  result  in  higher  incidence  of  adverse  effect.  E.g.  ulceration  of 
indomethacin-PEG 6000 dispersion.
 Difficulty in pulverization of solid dispersion.
 Drug carrier incompatibility.
 Poor flow and mixing properties.
 Sifting of the solid dispersions, which are usually soft and tacky.
CLASSIFICATION OF SOLID DISPERSIONS:
1. Simple eutectic mixtures15, 16.
Solid eutectic mixtures are usually prepared by rapid cooling of a comelt of two 
components  in  order  to  obtain  a  physical  mixture  of  very  fine  crystals  of  the  two 
components.  When  the  preparation  is  dissolved  in  aqueous  medium  the  carrier  will 
dissolve  rapidly,  releasing  very  fine  crystals  of  drug which  offers  large  surface  area 
thereby improvement in dissolution is effected. 
2. Solid solutions:
Solid solutions of a poorly water soluble drug dissolved in a carrier with relatively 
good  aqueous  solubility  are  of  particular  interest  as  a  means  of  improving  oral 
bioavailability. In the case of solid solutions, the drug's particle size has been reduced to 
its  absolute  minimum  viz.  the  molecular  dimensions  17 and  the  dissolution  rate  are 
determined by the dissolution rate of the carrier. By judicious selection of a carrier, the 
dissolution rate of the drug can be increased by up to several orders of magnitude. Solid 
solutions  can  be  classified  according  to  two  methods.  First,  they  can  be  classified 
according to their miscibility (continuous versus discontinuous solid solutions) or second, 
according to the way in which the solvate molecules are distributed in the solvendum 
(substitutional, interstitial or amorphous).
2.2.1. Continuous and discontinuous solid solutions:
2.2.1.1. Continuous solid solutions: In a continuous solid solution, the components are 
miscible in all proportions. Theoretically, this means that the bonding strength between 
the two components is stronger than the bonding strength between the molecules of each 
of the individual components. Solid solutions of this type have not been reported in the 
pharmaceutical literature to date. 
2.2.1.2. Discontinuous solid solutions: In the case of discontinuous solid solutions, the 
solubility of each of the components in the other component is limited.
2.2.2.  Substitutional  crystalline,  interstitial  crystalline  and  amorphous  solid 
solutions:
2.2.2.1.  Substitutional  crystalline  solid  solutions:  Classical  solid  solutions  have  a 
crystalline  structure,  in  which  the  solute  molecules  can  either  substitute  for  solvent 
molecules in the crystal lattice or fit into the interstices between the solvent molecules.  
Substitution is only possible when the size of the solute molecules differs by less than 
15% or so from that of the solvent molecules18.
 2.2.2.2.  Interstitial  crystalline  solid  solutions: In  interstitial  solid  solutions,  the 
dissolved molecules occupy the interstitial spaces between the solvent molecules in the 
crystal  lattice.  As in  the  case of  substitutional  crystalline  solid  solutions,  the  relative 
molecular size is a crucial criterion for classifying the solid solution type. In the case of 
interstitial  crystalline  solid  solutions,  the  solute  molecules  should  have  a  molecular 
diameter  that  is  no greater  than  0.59  of  the  solvent  molecule's  molecular  diameter 19. 
Furthermore, the volume of the solute molecules should be less than 20% of the solvent. 
2.2.2.3.  Amorphous  solid  solutions:  In  an  amorphous  solid  solution,  the  solute 
molecules are dispersed molecularly but irregularly within the amorphous solvent. Using 
griseofulvin in citric acid, Chiou and Riegelman20 were the first to report the formation of 
an amorphous solid solution to improve a drug's dissolution properties. Other carriers that 
were  used  in  early  studies  included  urea  and  sugars  such  as  sucrose,  dextrose  and 
galactose.  More  recently,  organic  polymers  such  as  polyvinylpyrrolidone  (PVP), 
polyethylene glycol (PEG) and various cellulose derivatives have been utilized for this 
purpose.
SOLID DISPERSION TECHNIQUES:
1. Melting or Fusion Method:
The  melting  or  fusion  method  was  first  proposed  by  Sekiguchi  and  Obi21 to 
prepare fast release solid dispersion dosage forms. In this method the physical mixture of 
drug and the water soluble carrier is heated directly until it is melted. The melted mixture 
is then cooled and solidified in an ice bath under vigorous stirring. The final mass was 
crushed, pulverized and sieved. The dispersion can also be cooled through the process of 
spray congealing using spray drying equipment. The melted material is sprayed onto cold 
metal surfaces, which forms pellet of the dispersion. This does not require grinding and 
therefore no alteration of the crystal modification of the drug occurs. E.g. solid dispersion 
of sulphamethoxazole, acetaminophen, chloramphenicol, tolazamide, steroids.
Advantages:
 Simplicity and economy.
 This method also advantageous for compounds, which do not undergo significant 
thermal degradation
 Super  saturation  of  a  solute  or  drug  in  a  system  can  often  be  obtained  by 
quenching of the melt rapidly from high temperature.
 Disadvantages:
 The  main  disadvantage  of  the  melt  method  includes  thermal 
degradation,  sublimation  and  polymeric  transformation,  which  can  affect  the 
physicochemical properties of the drug including its rate of dissolution.
 The  temperature  at  which  the  dispersion  solidifies  affects 
crystallization  rate  and may alter  both the size of the crystal  and hardness of the 
dispersion. This may result in tacky or glassy and unmanageable dispersions, which 
will require storage at elevated temperature to facilitate hardening.  
2. Solvent Evaporation Method:
 This method involves dissolving the drug and carrier in a suitable organic solvent 
followed by evaporation of the solvent to form solid dispersion involves dissolving the 
drug and carrier in a suitable organic solvent followed by evaporation of the solvent to 
form solid dispersion. The mass was then stored in dessicator,  pulverized and sieved. 
removal  is  accomplished  by  various  means.  The  most  common  approach  is  the 
application of reduced pressure at a fixed temperature to evaporate the organic solvent. 
Temperatures of 1250C for 25 minutes, 1150C for one hour22, -50c and reduced pressure 
followed by drying for 12 hours in vacuum have been used23. Spray drying is another 
approach by which solvent removal can be accomplished and it is probably the fastest 
way of removing solvent24,  25. The freeze drying technique is also employed to prepare 
solid dispersions by removal of aqueous solutions26, 27. E.g. solid dispersion of β-carotene-
PVP, griseofulvin-PVP and reserpine-deoxy cholic acid.
Advantages:
 The procedure is suitable for drugs that are thermo labile.
 The thermal decomposition of drugs or carriers can be prevented because of the 
low temperature required for the evaporation of the organic solvents. 
 For aqueous system, frozen temperature can be used to evaporate the solvent, 
which can enhance the integrity of the drug.
 Disadvantages:
 Difficulty in complete removal of solvent.
 Finding a suitable solvent that will dissolve both the drug and carrier is 
very difficult.
 Plasticization  of  some  polymers  such  as  poly  vinyl  pyrrolidone  has 
occurred with the use of some solvents.
 It is important that the rate of evaporation of a solvent is controlled so as to 
control the particle size of the drug. This in turn will affect the rate of dissolution of 
the drug in the solid dispersion.
3. Fusion-Solvent Method:
  In the fusion solvent method, a carrier(s) is/are melted and the drug(s) is/are 
incorporated  in  the  form of  a  solution.  If  the  carrier  is  capable  of  holding a  certain  
proportion of liquid yet maintaining its solid properties, and if the liquid is innocuous, the 
need for removal is eliminated.  This method is particularly useful for drugs that have 
high melting points are that are thermo labile. The feasibility of the method has been 
demonstrated  for  spironolactone  and  griseofulvin  dispersions  in  polyethylene  glycol 
6000(PEG 6000) 28. E.g. solid dispersion of clofibrate, methyl salicylate, benzyl benzoate.
 MECHANISM  OF  INCREASED  DISSOLUTION  RATE  BY  SOLID 
DISPERSION SYSTEM:
 In  the  case  of  glass  solutions,  and  amorphous  dispersions, 
particle size is reduced to a minimum level. This can result in an enhanced dissolution 
rate due to both an increase in surface area and solubilization.
 The carrier  material  as it  dissolves may have a solubilization 
effect on the drug.
  The carrier material may also have an enhancing effect on the 
wettability  and dispersibility  of  the  drug in  the  dissolution  medium.  Then should 
retard  any  agglomeration  or  aggregation  of  the  particles,  which  can  slow  the 
dissolution process.
 Formation of metastable dispersion that has a greater solubility 
would result in faster dissolution rates.
APPROACHES  TO  IMPROVE  THE  SOLUBILITY  OR  TO  INCREASE  THE 
AVAILABLE SURFACE AREA FOR DISSOLUTION: 3.
I. Physical modifications:
• Particle size
o Micronization
o Nanosuspensions
• Modifications of the crystal habit
• Polymorphs
• Pseudo polymorphs (including solvates)
• Complexation/solubilization
o Use of surfactants
o Use of cyclodextrines
• Drug dispersion in carriers
o Eutectic mixtures
o Solid dispersions (non-molecular)
o Solid solutions
II. Chemical modification:
• Soluble prodrugs
• Salts
CARRIERS USED FOR SOLID DISPERSION SYSTEMS: 3
1. Polyethylene glycols (PEGs)
2. Polyvinylpyrrolidone (PVP)
3. Polyvinyl groups 
o Polyvinyl alcohol (PVA)
o Crospovidone 
o Polyvinylpyrollidone-polyvinylacetate copolymer (PVP-PVA)
4. Cellulose derivatives  
o Hydroxypropylmethylcellulose (HPMC)
o Hydroxypropylcellulose (HPC)  
o Carboxymethylethylcellulose (CMEC)
o Hydroxypropylmethylcellulose phthalate (HPMCP)
5. Polyacrylates and polymethacrylates
o Eudragit E 
o Eudragit L
6. Urea
7. Sugar, polyols and their polymers
o Dextrose 
o Sucrose 
8. Emulsifiers 
o Sodium Lauryl Sulphate 
o Tween 80
9. Organic acids and their derivatives
o Succinic acid 
o Citric acid
10. Other carriers    
o Phospholipid       
o Pentaerythritol
NON – STEROIDAL ANTI-INFLAMMATORY DRUGS30
Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) are among the most widely 
used  for  all  therapeutic  agents.  They  are  frequently  prescribed  for  'rheumatic' 
musculoskeletal complaints and are often taken without prescription for minor aches and 
pains.
NSAIDS include a variety of different agents of different chemical classes. Most 
of these drugs have three major types of effect.
• Anti-inflammatory effects: Modification of the inflammatory reaction.
• Analgesic effect: reduction of certain sort of pain
• Antipyretic effect: lowering of a raised temperature.
In general,  all  of  these effects  are  related  to  the primary action  of the  drugs-
inhibition of arachidonate cyclooxygenase (COX) and thus inhibition of the production of 
prostaglandins and thromboxanes, though some aspects of the action of individual drugs 
may occur by different mechanisms.
ANTIPYRETIC EFFECTS
Normal body temperature is  regulated  by a centre  in the hypothalamus which 
ensures a balance between heat loss and heat production. Fever occurs when there is a 
disturbance  of  this  hypothalamic  'thermostat'  that  leads  to  the  set  point  of  body 
temperature  being  raised.  NSAIDs  reset  the  thermostat.  The  mechanisms  of  the 
antipyretic  action  of  the  NSAIDs  are  thought  to  be  due  largely  to  inhibition  of 
prostaglandin production in the hypo-thalamus. 
ANALGESIC EFFECT 
NSAIDs are mainly effective against pain associated with inflammation or tissue 
damage because they decrease production of the prostaglandins that sensitive nocicepters 
to inflammatory mediators such as bradykinin. Therefore they are effective in arthritis,  
bursitis,  pain of muscular  and vascular  origin,  toothache,  dysmenorrhoea,  the pain of 
postpariem  states  and  the  pain  of  cancer  metastasis  in  bone,  all  conditions  that  are 
associated with increased prostaglandin synthesis. There is some evidence that they have 
a central effect by an action mainly in the spinal cord.Clinical data indicate that certain 
NSAIDs  are  effective  in  the  control  of  some  types  of  severe  pain  unrelated  to 
inflammation.
ANTI – INFLAMMATORY EFFECT: 
Drugs such as the NSAIDs reduce mainly those components of the inflammatory 
and immune response in which the products of COX-2 action play a significant part, 
namely:
• Vasodilatation 
• Oedema
• Pain
COX inhibitors, per se, have no effects on those processes that contribute to tissue 
damage in chronic inflammatory conditions such as rheumatoid arthritis, vasuclitis and 
nephritis.  Infact,  because  some  prostaglandins  decrease  lysosomal  enzyme  release 
reduces the generation to toxiz O2 products inhibit lymphocyte activation, NSAIDs could 
actually exacerbate tissue damage in the long term.
CLASSFICATION OF NSAIDS: 31
The various analgesic –antipyretic anti-inflammatory agents are classified as
1. Acidic Drugs 
a. Salicylates: 
     E.g. Salicylic acid, Apirin
b. Para-amino phenols: 
     Eg:Paracetamol
c. Pyrazolones: 
Eg: Phenylbutazone, Suxibuzone 
d. Indole acetic acids:
Eg:Indomethacin, clamidoxic acid 
e. Propionic acids:
Eg: Ibuprofen, Diclofenac
f. Aryl anthranilic acids:
Eg: Meclofenamic acid, Tolfenamic acid
g. Miscellaneous agents:
Eg: Piroxicam, Fenoxicam
2. Basic Drugs
Eg: Timegadine, inhibits neutrophil degranulation and superoide production 
3. Non-Acidic Drugs:
     Eg: Indoxole Nictimodole 
CLASSIFICATION OF NSAID’S BY CHEMICAL STRUCTURE:
1. Carboxylic Acid Groups: 
♦ Salicylates (Acetylsalicylate, Choline Salicylate, Diflunisal, Magnesium choline 
Salicylate, Magnesium Salicylate, Salsa late)
♦ Acetic Acids (Diclofenac sodium, Diclofenac potassium, Etodolac, Indomethacin, 
Ketorolac, Nabumetone, Sulindac, Tolmetin)
♦ Propionic  acids  (Carprofen,  Fenoprofen,  Flubiprofen,  Ibuprofen,  Ketoprofen, 
Loxoprofen, Naproxen, Naproxen sodium, Oxaprozin, Vedaprofen)
♦ Anthranilic acids (Meclofenamic acid, Meclofenamate sodium,Tolfenamic acid) 
♦ Phenlylacetic acids (Acetaminophen)
♦ Amino nicotinic acids (Flunixin)
♦ Indole Analogs (Indomethacin, Nabumetone, Ketorolac, Etodolac,)
2. Enolic Acid Groups (which doesn't have carboxylic group but acid due to the 
enolic Hydroxy substituent)
♦ Pyrazolones  (Phenylbutazone,  Oxyphenbutazone,  Dipyrone, 
Ramifenazone)
♦ Oxicams (Aceclofenac, Piroxicam, Tenoxicam)
3.    Coxibs: Celecoxib, Rofecoxib, Vladecoxib, Parecoxib, Etoricoxib 
4.    Gold Salts:  Auranofin, Gold sodium thiomalate, Aurothioglucose 
MECHANISM OF ACTION
The main action of NSAIDs is inhibition of arachidonate cyclo oxygenase. COX 
is a bifunctional enzyme, having two distinct activities, the main cyclo-oxygenase action 
which gives PGG2, and a peroxidase action which converts PGG2 to PGH2. Different 
NSAIDs inhibit the enzyme by different mechanisms.
BIOSYNTHESIS OF PROSTAGLANDINS: 
The biochemical effect of NSAIDs includes inhibition of lysosomal membrane 
stabilization, inhibition of the biosynthesis of mucopolysaccharides, uncoupling oxidative 
phosphorylation,  fibrinolytic  activity,  sulfahydryl  disulfide  stabilization.  Collagenase 
production and at times suppression of lymphocytic functions. 
Cyclooxgenase catalyses two enzymatic process:
♦ The incorporation of oxygen in a dioxygenase step to form PGG2 and 
♦ The subsequent  peroxidation  to PGH2. The reaction  is  initiated  by the 
stereospecific abstractin of hydrogen at C13 followed by oxygen attach at C11  and 
C15.
♦ Most  of  NSAIDs  act  by  inhibiting  cyclooxygenase  by  preventing  the 
abstractin of hydrogen from C13 and therefore peroxidatin at C11 and C15.
Prostaglandins potentiate the early inflammatory response causing vasodilatation, 
increases permeability, facilitating cellular infiltration land sensitizing the pain receptors 
to bradykinin. The NSAIDs inhibit both the synthesis and release of prostaglandins.
ADVERSE EFFECTS: 31 
1. Side effect that occurs at analgesic dose (0.3-1.5g/day)
Nausea, vomiting, epigastric distress, increased occult blood loss in stools. The most 
important adverse effect of NSAIds is gastric mucosal damage and peptic ulceration.  
2. Hypersensitivity and idiosyncrasy
Though infrequent,  there can be serious reactions,  which include rashes,  urticaria, 
rhinorrhea, angiodema, asthama and anaphylactic reaction. Profuse gastric bleeding 
occurs in rare instance.
3. Anti – inflammatory dose (1-2g/day)
It will produce the syndrome called salicylism- dizziness, tinnitus, vertigo, reversible 
impairment of hearing and vision, excitement and mental confusion, hyperventilation 
and electrolyte imbalance.
4. Gastric Mucosal Damage
All NSAIDs to varying extent produce gastric pain, mucosal erosion or ulceration and 
blood loss.
5. Renal effect
Conditions leading to hypovolemia, decreased renal perfusion and Na+ loss induce 
renal prostaglandin synthesis which brings about intra renal adjustment by promoting 
vasodilation, inhibiting tubular reabsorption and opposing ADH action.
Table.1 Solid dispersion of therapeutic agents
Drug Carriers Method Type of solid dispersion
Effect of 
dissolution 
rate
Allopurinol PVP S Not studied Increased
Benzybenzoate PEG 6000 MS Not studied Increased
Chloramphenicol Urea M Solid solution Increased
Clofibrate PEG 6000 MS Not studied Increased
Corticosteroids Sugars M Not studied Increased
Diazepam PEG 4000 M solid solution Not studied
Griseofulvin
Succinic 
Acid
M Solid solution Increased
PVP S Not studied Increased
PEG- 4000 MS Not studied Increased
PEG- 6000 M,S Not studied Increased
PEG 2000 M Not studied Increased
Citricacid M Glass 
suspension
Increased
Indomethacin PEG 6000 M Not studied Increased
Methylsalicylate PEG 6000 S Not studied Increased
Paracetamol Urea M Solid solution Increased
Mannitol M Eutetic Increased
Primidone Citric acid M Glass solution Increased
Reserpine PVP S Not studied Increased
Sulfathiazole Urea M Simple 
eutectic
Not studied
Tobultamide
PEG- 4000 S Not studied Increased
PEG-6000 S Not studied Increased
PEG4000 M,S Not studied Increased
PEG-2000 M,S Mono acetic Not studied
PVP S Not studied Increased
PEG-8000 M,S Not studied Increased
PVP S Not studied Increased
PEG-6000 S Not studied Increased
PEG-4000 M Not studied Increased
 *M-Melting Method S- Solvent Method MS- Melting solvent method
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Aceclofenac:
Aceclofenac is from the class of Non Steroidal Anti Inflammatory Drug (NSAID), 
related to diclofenac. It is a derivative of aryl acetic acid.  
Chemical name: 33  
[[[2-[(2, 6-dichloro phenyl) amino] phenyl] acetyl] oxy] acetic acid. 
Empirical formula: 33   
C16H 13Cl2 NO4
Chemical Structure: 33  
                                        
CH2
O
O
CH2
COOH
NH
ClCl
Characteristics: 34
White or almost white, crystalline powder. Practically insoluble in water, freely 
soluble in acetone, soluble in alcohol. Melting point is 149°-150°C.
Pharmacology: 
The  mode  of  action  of  aceclofenac  is  largely  based  on  the  inhibition  of 
prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclo oxygenase 
(COX),  which is  involved in  the production  of prostaglandins.  Aceclofenac  has  been 
shown  to  exert  effect  on  a  variety  of  mediators  of  inflammation.  The  drug  inhibits 
synthesis of the inflammatory cytokines interleukin (IL)-1β and inhibits prostaglandin E2 
(PGE2) production Invitro data indicate inhibition of COX 1&2 by aceclofenac in whole 
blood assays; with selectively COX 2 is evident.
In contrast to some other NSAIDs aceclofenac has shown stimulatory effect on 
cartilage matrix synthesis that may be linked to the ability of the drug to inhibit (IL) - 1β 
activity. There is also evidence that aceclofenac stimulates the synthesis of IL-1 receptor 
antagonist in human articular chondrocytes subjected to inflammatory stimuli and that 4’- 
hydroxyl aceclofenac has chondro protective properties attributable to suppression of (IL) 
- 1β mediated promatrix metallo proteinase production and proteoglycan release. 
In patients  with osteoarthritis  of the knee,  aceclofenac decreases pain,  reduces 
diseased  severity  and  improves  the  functional  capacity  of  the  knee.  It  reduced  joint 
inflammation,  pain  intensity  and  the  duration  of  morning  stiffness  in  patients  with 
rheumatoid arthritis. The duration of morning stiffness and pain intensity are reduced and 
spinal motility improved, by aceclofenac in patients with ankylosing spondylitis.
Pharmacokinetics:
Aceclofenac is rapidly and completely absorbed after oral administration. Peak 
plasma concentration is reached 1-3 hours after an oral dose. The drug is highly protein 
bound  (>99%).  The  presence  of  food  does  not  alter  the  extent  of  absorption  of 
aceclofenac but the absorption rate is reduced. The plasma concentration of aceclofenac 
was approximately twice that in synovial fluid and multiple doses of drug in patients with 
knee pain and synovial fluid effusion. 
Aceclofenac is metabolized to a major metabolite, 4’- hydroxyl aceclofenac and 
to  a  number  of  other  metabolites  including  5-hydroxy  aceclofenac,  4’-  hydroxyl 
diclofenac, diclofenac and 5- hydroxyl diclofenac. These other metabolites account for 
the fate of approximately 20% of each dose of aceclofenac. Renal excretion is the main 
route of elimination of aceclofenac with 70-80% of an administered dose found in the 
urine, mainly as the glucuronides of aceclofenac and its metabolites. Of each of dose of 
aceclofenac, 20% is excreted in the faeces. The plasma elimination half life of the drug is 
approximately 4 hours. 
Indications:
Aceclofenac is indicated for the relief of pain and inflammation associated with 
rheumatoid arthritis, oesteo arthritis is ankylosing spondylitis. 
Contraindications:
Aceclofenac should not be administered to patients hypersensitive to aceclofenac 
or  other  NSAID’s,  or  patients  with history of  aspirin  or  NSAID’s  related  allergic  or 
anaphylactic  reactions  or with peptic  ulcers or GI bleeding,  moderate  of severe renal 
impairment.
Drug interactions:
Drug interactions associated with aceclofenac are similar to those observed with 
other NSAID’s. Aceclofenac may increase plasma concentrations of lithium, digoxin and 
methotrexate, increase the activity of anti coagulants, inhibit activity of diuretics, enhance 
cyclosporine  nephrotoxicity  and  precipitate  convulsions  when  co  administered  with 
quinolone  antibiotics.  The  co  administration  of  aceclofenac  with  other  NSAID’s  or 
corticosteroids may result in increased frequency of adverse events.
Adverse drug reactions:
Aceclofenac is well tolerated with most adverse events being minor and reversible 
and  affecting  mainly  the  GI  system.  Most  common  events  includes  dyspepsia,  and 
abdominal pain, dizziness, vertigo, pruritus, rash and dermatitis have been reported with 
aceclofenac,  but  the  incidence  of  these  events  is  less  than  5%.  Increases  blood  urea 
nitrogen and blood creatinine levels have also been reported with aceclofenac treatment. 
As with other NSAID’s, aceclofenac can elevate circulating levels of hepatic enzymes. 
Dose and Administration:
The usual dose of aceclofenac is 100mg given twice daily by mouth. One tablet in 
the morning and one in the evening. There is some evidence that the dose of aceclofenac 
should be reduced in patients with hepatic impairment and it is suggested that an initial 
daily dose of 100mg be used.   
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POLY VINYL PYRROLIDONE
1. Non proprietary names:
             BP: Povidone
             JP: Povidone
             Ph Eur: Povidonum
             USP: Povidone
2. Synonyms:
E1201;  Kollidon:  plasdone;  PVP:  Poly  [1-(2-oxo-1-  pyrrolidinyl)  ethylene]; 
polyvidone; 1-vinyl-2- pyrrolidionone polymer
3. Chemical name:
1-Ethenyl-2-pyrrolidinone homo polymer 
 4. Empirical formula:
(C6H9NO)n 
5. Molecular weight:
2500-3,000,000
Table .2 Approximate molecular weights for different grades of 
povidone
K value Approximate molecular wt
12 2500
15 8000
17 10,000
25 30,000
30 50,000
60 400,000
90 1,000000
120 3000000
6. Functional category:
Disintegrant, dissolution aid, suspending agent, tablet binder.
7. Description:
Povidone occurs  as  a  fine,  white  to  creamy-white  colored,  odorless  or  almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres.
8. Typical properties:
Acidity/alkalinity : pH = 3.0-7.0 (5% w/v aqueous solution)
True density : 1.180g / cm3
Melting point : softens at 150oC
Moisture content : Povidone  is  very  hygroscopic  significant  amounts  of  moisture. 
being absorbed at low relative humidities
9. Solubility:
Freely  soluble  in  acids,  chloroform,  ethanol,  ketones,  methanol  and  water, 
practically insoluble in ether, hydrocarbons and mineral oil.    
10. Stability and storage conditions:
Povidone darkens to some extent on heating at 150oC, with a reduction in aqueous 
solubility.   It  is  stable  to  a  short  cycle  of  heat  exposure  around  110-130oC.  Steam 
sterilization of aqueous solution does not alter its properties. 
11. Safety:
Povidone has been used in pharmaceutical formulations for many years,  being 
first used in the 1940s as a plasma expander, although it has now been superseded for this 
purpose by dextran.29
12. Application in pharmaceutical formulation or technology:
i. It is primarily used in solid-dosage forms.
ii. In  tableting,  povidone  solution  are  used  as  binders  in  wet  granulation 
processes.
iii. It is also added to powder blends in the dry from and granulated inside by the 
addition of water, alcohol or hydro alcoholic solutions.
iv. It is used as a solubilizer in oral and parenteral  formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid dosage forms.
v. Used as a suspending, stabilizing or viscosity-increasing agent in a number of 
topical and oral suspensions and solutions.
vi. The solubility of a number of poorly soluble active drugs may be increased by 
mixing with povidone.
vii. Special grades of pyrogen-free povidone are available and have been used in 
parenteral formulations.
POLYVINYL ALCOHOL 
1. Nonproprietary Names 
     USP: Polyvinyl alcohol  
2. Synonyms : 
     Airvol; Elvanol; Gohsenol; PVA; vinyl alcohol polymer.
3. Chemical Name:
     Erhenol, Homopolymer 
4. Empirical Formula :
     (C2H2O) n
Polyvinyl alcohol is water – soluble synthetic polymer represented by the formula 
(C2H2O)n    The value of n for commercially available  materials  lies between 500 and 
5000, equivalent to a molecular weight range of approximately 20000-200 000. 
Table .3 Commercially available grades of polyvinyl alcohol.
Grade Molecular weight
High viscosity ~ 200 000
Medium viscosity ~ 130 000
Low viscosity ~ 20 000
   
5. Molecular Weight:
     (20 000 -200 000)  
6. Functional Category: 
Coating agent; lubricant; stabilizing agent; viscosity –increasing agent.  
7. Description:
Polyvinyl alcohol occurs as an odorless, white to creamcolored granular powder. 
8. Typical Properties: 
Melting point: 
• 228°C for particularly hydrolyzed grades 
• 180-190 C for partially hydrolyzed grades 
Refractive index:
N25/D = 1.49-1.53
Solubility: 
Soluble in water; insoluble in organic solvents. 
Specific gravity: 
1.19-1.31 for solid at 25°C   
1.02 for 10% w/v aqueous solution at 25°C
Specific heat:
1.67 J/g (0.4 cal/g)
Table .4 Viscosity of polyvinyl alcohol:
Grade
Dynamic viscosity of 4% w/v
aqueous solution at 20°C (mPas)
High viscosity 40.0-65.0
Medium viscosity 21.0-33.0
Low viscosity 4.0-7.0
9. Stability and Storage Conditions:
Polyvinyl alcohol is when stored in a tightly sealed Polyvinyl in a cool, dry place.  
Preservatives may be in added to the solution if extended storage is required. Polyvinyl 
alcohol undergoes slow degradation at 100°C rapid degradation at 200°C. It is stable on 
exposure to light. 
10. Safety:
Poly vinyl Alcohol is generally considered a non toxic material. It is non irritant 
to  the skin  and eyes  concentrations  up to  10% concentrations  up to  7% are used  as 
cosmetics.
REVIEW OF LITERATURE
• Franco et al., 36 (2001) have studied dissolution properties and anticonvulsant activity 
of  phenytoin-polyethylene  glycol  6000  and  polyvinylpyrollidone  K-30  solid 
dispersions with different drug to carrier ratios were prepared by the solvent method. 
Among the various ratios, drug solubility and dissolution rate are improved by these 
formulations, particularly with SDPEG 1/20 and SDPVP 1/20 systems. Storage was 
found to influence the stability of the solid dispersions. . By maximal electroshock 
test, it was found that the intraperitoneal administration in mice of the SDPEG 1/20 
and  SDPVP  1/20  systems  exhibited  anticonvulsant  activity  similar  to 
diphenylhydantoin sodium salt.
• Kazunari  et  al. 37,  (2003)  have  established  new  preparation  method  for  solid 
dispersion formulation of tacrolimus using three different carriers like polyethylene 
glycol  6000  (PEG  6000),  polyvinylpyrollidone  (PVP)  and 
hydroxypropylmethylcellulose (HPMC) were prepared by the conventional  solvent 
method, in which tacrolimus and the carrier was completely dissolved in the mixture 
of dichloromethane and ethanol. In new method solid dispersion of tacrolimus was 
prepared without  using dichloromethane as a solvent.  The in  vivo oral  absorption 
study in dogs showed that bioavailability of tacrolimus from SDF with HPMC was 
remarkably  improved  compared  with  the  crystalline  powder.  It  was  clarified  that 
HPMC is the most appropriate carrier for SDF of tacrolimus. The physicochemical 
properties of SDF with HPMC prepared by the new method were the same as those of 
SDF  prepared  by  the  conventional  solvent  method.  They  concluded  the 
pharmacokinetic  parameters  after  oral  administration  in  monkeys  showed  no 
significant difference (P >0.01) between solid dispersion s with HPMC prepared by 
the two methods.
• Anant et al. 38, (2004) were characterized solid dispersion of cur cumin–PVP obtained 
by spray drying  they revealed  the  changes  in  solid  state  during  the  formation  of 
dispersion  by  physical  characterization  studies  and  also  solid  dispersion  showed 
complete  dissolution  with  in  30  minutes.  This  in  turn  may  aid  in  improving 
bioavailability and dose reduction of the drug.
• Sethia and Squillante39 (2004) were prepared solid dispersion of carbamazepine in 
PVP K30 by conventional solvent evaporation and supercritical methods. They have 
suggested  that  the  best  intrinsic  dissolution  rate  (IDR)  was  obtained  for  super 
critically processed CBZ/PVP K30 that was four-fold higher than pure CBZ and the 
supercritical-based  process  produced  solid  dispersions  with  IDR  better  than 
conventional solid dispersions augmented with amphiphilic carriers.
• Susumu et al.,40 (2005) studied the effects of water content in physical mixture and 
heating  temperature  on  crystallinity  of  troglitazone-PVP  K30  solid  dispersions 
prepared by closed melting method. The apparent crystallinity of troglitazone in the 
SDs decreased with increase in water content in the PM. In particular, SDs prepared 
by heating at 130 and 150°C showed 0% apparent crystallinity when the water content 
in the PM were more than 13 and 8%, respectively. When the heating temperature 
used was higher than the glass transition temperature of PVP plasticized with water, 
troglitazone  crystals  were  dissolved  in  the  rubbery  PVP.  Therefore,  even  if  the 
heating temperature is lower than the melting point of troglitazone during preparation, 
controlling the water content in the PM at a high level can produce a troglitazone SD 
with 0% apparent crystallinity.
• Masayasu et al., 41 (2005) have studied the inhibition of a solid phase reaction among 
excipients  that  accelerates  drug  release  from  a  solid  dispersion  with  aging.  A 
modified  release  product  of  a  therapeutic  drug  for  hypertension,  Barnidipine 
hydrochloride, was developed. The drug product consisted of solid dispersion based 
on a matrix of carboxymethylethylcellulose (CMEC), which was produced using the 
spray-coating method. The molecular bases of dissolution of the drug substance from 
those matrices were investigated. The molecular weight of CMEC was found to be a 
dominant  factor  that  determined  dissolution  kinetics,  which  followed  zero-order 
release,  suggesting  an involvement  of an osmotic  pumping mechanism.  The solid 
phase reaction advanced differentially in the solid dispersion depending on the degree 
of phase separation set initially. The use of non-aqueous solvents and/or a decrease in 
the  coating  temperatures  inhibited  the  occurrence  of  phase  separation  upon 
production, thereby preventing the formation of CMEC-rich phases where the solid 
phase reaction occurred during storage.
• Toshio  et  al., 42 (2005) were investigated  the release mechanism of poorly water-
soluble drug from the extended release solid dispersion systems with water insoluble 
ethyl cellulose (EC) and water soluble hydroxypropylmethylcellulose (HPMC) (1:1). 
Indomethacin  (IND)  was  used  as  a  model  of  poorly  water-soluble  drug.  The 
dissolution  behavior  of  IND depended  on  the  structures  of  EC–HPMC matrices, 
which were overned by the preparation method. In addition, the dissolution behavior 
showed pH dependency that the dissolution rate of IND was slower in acidic medium 
than that in neutral medium. The experimental results revealed that the hydrophobic 
interaction between IND and EC occurred under lower pH and strongly delayed the 
dissolution rate of IND. The relationship between this hydrophobic interaction and 
the dissolution rate of IND was also proposed.
• Hirofumi et al., 43 (2005) was prepared the solid dispersion particles of indomethacin 
(IMC)  with  different  types  of  silica,  non-porous  (Aerosil  200)  or  porous  silica 
(Sylysia 350) by using spray-drying method. In comparing the effect of the type of 
the silica particles, the dissolution rate of solid dispersion particles with Sylysia 350 
was faster than that with Aerosil 200. The formulation amount of IMC did not affect 
on the amorphous state of IMC in the resultant solid dispersion particles in powder X-
ray  diffraction  patterns.  The  dissolution  rate  of  IMC  from  the  solid  dispersion 
particles with Sylysia 350 was faster than that of Aerosil 200 irrespective of IMC 
content. In stability test, amorphous IMC in the solid dispersion particles with each 
silica particles did not crystallize under storing at severe storage conditions (40°C, 
75% RH) for 2 months, while amorphous IMC without silica easily crystallized under 
same conditions.
• Jingjun et al., 44 (2006) were elucidate the controlled-release mechanism of a poorly 
water-soluble  drug  from  microparticles  of  ammonio  methacrylate  copolymer  and 
ethylcellulose binary blend prepared by a phase-separation method, nifedipine-loaded 
microparticles with different levels of drug loading were evaluated by micromeritic 
properties, drug physical state, matrix internal structure, drug dissolution, and release 
modeling. Moreover, study results indicated that even though drug loading did not 
significantly  affect  the  microparticle  size  distribution  and  morphology,  nifedipine 
release rate from those microparticles was more or less influenced by the level of 
drug loading,  depending on matrix  formulation.  At higher  levels  of  drug loading, 
probably due to formation of solid nifedipine domains in microparticles, a change in 
the release kinetics was observed.
• Drooge  et  al., 45 (2006) were characterized  the  molecular  distribution  of  drugs  in 
glassy  solid  dispersions  at  the  nano-meter  scale,  using  differential  scanning 
calorimetry  and  gravimetric  water  vapour  sorption  techniques.  The  molecular 
distribution in fully amorphous solid dispersions consisting of poly(vinylpyrrolidone) 
(PVP)–diazepam and inulin–diazepam was studied. One glass transition temperature 
(Tg),  as  determined  by  temperature  modulated  differential  scanning  calorimetry 
(TMDSC), was observed in PVP–diazepam solid dispersions prepared by fusion for 
all drug loads tested (10–80 wt.%). These observations indicate that diazepam was 
dispersed in PVP on a molecular level. However, in PVP–diazepam solid dispersions 
prepared by freeze drying, two  Tg’s were observed for drug loads above 35 wt.% 
indicating phase separation. One  Tg indicated the presence of amorphous diazepam 
clusters,  the other  Tg was attributed  to  a PVP-rich phase in which diazepam was 
dispersed on a molecular level. Water vapour sorption (DVS) experiments revealed 
that the PVP-matrix was hydrophobised by the incorporated diazepam. TMDSC and 
DVS results were used to estimate the size of diazepam clusters in freeze dried PVP–
diazepam  solid  dispersions,  which  appeared  to  be  in  the  nano-meter  range.  The 
inulin–diazepam solid dispersions prepared by spray freeze drying showed one Tg for 
drug loads up to 35 wt.% indicating homogeneous distribution on a molecular level. 
For higher drug loads, a Tg of diazepam as well as a Tg of the inulin-rich phase was 
observed, indicating the formation of amorphous diazepam clusters.
In  contrast  to the PVP–diazepam solid dispersions,  DVS-experiments  revealed  that  inulin  was not 
hydrophobised by diazepam. Consequently,  the size of diazepam clusters could not be estimated. It 
was concluded that TMDSC enables characterization and quantification of the molecular distribution 
in amorphous solid dispersions.  When the drug reduces the hygroscopicity of  the carrier,  DVS in 
combination with TMDSC can be used to estimate the size of amorphous drug clusters.
• Nora46 (2006)  has  studied  stabilization  of  solid  dispersions  of  nimodipine  using 
macrogol  cetostearyl  ether,  macrogol  glycerol  monostearate,  polysorbate  60,  ceto 
stearyl  alcohol,  and  glycerol  monostearate  and  sodium lauryl  sulphate  as  well  as 
hydroxypropyl cellulose butylmethacrylat-  (2-dimethylaminoethyl) 
methacrylatmethyl  methacrylat-copolymer,  polyacrylic  acid,  polyvinylalcohol  and 
povidone  K17  were  included  in  the  study.Among  these  carriers  povidone  K17 
effectively  prevents  recrystallization  in  solid  solutions  containing  of  nimodipine 
during storage at +25 0C over silica gel thereby ensuring a substantial increase in the 
dissolution rate.
• Eun-Jung et al., 47 (2006) has studied the dissolution rates of felodipine using PVP 
and HPMC carriers by solvent wetting method. It could be shown that the dissolution 
rates of felodipine in PVP and HPMC solid dispersion were much faster than those 
for the corresponding physical mixtures. However, dissolution profiles were found to 
depend on the carrier  used; the dissolution rate of felodipine increased slowly for 
solid dispersions prepared using HPMC, whereas rapid initial dissolution rates were 
observed  for  solid  dispersions  prepared  using  PVP  or  poloxamer.  Increases  in 
dissolution  rates  were  partly  dependent  on  the  ratios  of  felodipine  to  carrier.  No 
significant  changes in crystal  form were observed by X-ray diffraction or thermal 
analysis, and no significant changes in dissolution rate were observed when sorbitol 
and mannitol were used as carriers.
• Ningyun et al., 48 (2007) studied the dissolution enhancement of silymarin- PVP solid 
dispersion pellets prepared by a one step fluid bed coating technique. They reported 
that the dissolution rate of silymarin-PVP solid dispersion was enhanced greatly at 
drug carrier ratio of over 4:1. The results of the central composite design suggested 
that  both  PVP/SM  ratio  and  coating  weight  gain  affected  the  dissolution  rate 
significantly.  Second-order  or  third-order  polynomial  non-linear  equations  were 
employed  to  estimate  the  relationship  between  dissolution  responses  and the  two 
independent variables. Response surface graphs were delineated based on the best-of-
fit equations and the optimal experimental range was identified as: PVP/SM, 4/1-5/1; 
coating  weight  gain,  80%-120%.  The  results  indicate  that  the  fluid-bed  coating 
technique has the potential use in the preparation of solid dispersions.
• Naveen  et al., 49 (2007) have studied enhancement of dissolution and mathematical 
modeling  of  drug release  of a  poorly water-soluble drug (rofecoxib)  using water-
soluble carriers viz. polyethylene glycols (PEG 4000 and 6000), polyglycolized fatty 
acid  ester  (Gelucire  44/14),  polyvinylpyrollidone  K25  (PVP),  poloxamers  (Lutrol 
F127  and  F68),  polyols  (mannitol,  sorbitol),  organic  acid  (citric  acid)  and 
hydrotropes.  All  the  solid  dispersions  showed  dissolution  improvement  vis-a`-vis 
pure  drug to  varying  degrees,  with  citric  acid,  PVP and poloxamers  as  the  most 
promising carriers. Solid-state characterization techniques revealed that distinct loss 
of  drug crystallinity  in  the formulation,  ostensibly accounting for enhancement  in 
dissolution rate.
MATERIALS AND METHODS
Table.5 Materials used
Name of the materials Name of company
Aceclofenac Anglo-french Drug Industries Limited
PVP 10 Sigma Aldrich Ltd
PVP 40 Sigma Aldrich Ltd
PVP 360 Sigma Aldrich Ltd
PVA 8136 Sigma Aldrich Ltd
Ethanol Changshu Yangyuan Chemical
Sodium hydroxide SD fine chem. Ltd
Potassium dihydrogen phosaphate Ranchem Ltd
Glacial acetic acid SD fine chem. Ltd
Toluene Qualigens
Ethyl acetate SD fine chem. Ltd
Potassium bromide Qualigens
Table .6 Equipments used:
Name of equipment Name of company
Vacumm pump Gelman sciences
Dissolution apparatus Electoral TDT – 08L 
UV spectrometer Jasco V 530
Alphadigidoc TM Alpha Innotech corporation
FT IR  spectrometer (Jasco-FT-IR 8201 PC)
pH testr 1 (water proof) Oakton instruments.
 ANALYTICAL METHOD FOR ACECLOFENAC50  
1. Spectrophotometric method for the estimation of aceclofenac in tablets: 
A standard  solution  containing  1mg/ml  of  aceclofenac  was  prepared  in  methanol  by 
dissolving  50mg of  pure  drug aceclofenac  in  50  ml  of  methanol.  From this  solution 
working atandard solutions of concentrations 0-20mcg/ml of aceclofenac were prepare 
dby dilution with mwthanol. The absorbance of the solutions was measured at 275nm 
against reagent blank.   
 2. Analytical methodology used in the present study:
Procedure for standard graph preparation of aceclofenac 
About 10mg of aceclofenac was accurately weighed and dissolved in 100 ml of 
ethanol. This will give the stock solution of concentration 100mcg/ml.
From  this  solution  pipette  out  0.4,0.8,1.2,1.6  2.0  and  2.4  ml,  which  were 
transferred into a series of 10ml volumetric flasks and the final volume was brought up to 
10ml with pH 7.4 phosphate buffer to get a concentration of 4-24 mcg/ml. A blank was 
also prepared.  The absorbance was measured  at  273 nm and the standard graph was 
plotted against concentration (mcg/ml) Vs absorbance. The results were given in table.7 
and figure.2. 
Table.7 Standard graph of aceclofenac:
Concentration (mcg/ml) Absorbance at 273 nm
0 0.000
4 0.093
8 0.199
12 0.294
16 0.391
20 0.490
24 0.592
Fig.2 Standard graph of aceclofenac at pH 7.4 phosphate buffer:
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EXPERIMENTAL METHODOLOGY
PREPARATION  AND  CHARACTERIZATION  OF  ACECLOFENAC  SOLID 
DISPERSION: 
Solid  dispersion  technology  can  be  used  to  improve  the  in  vitro  and  in  vivo 
dissolution properties of poorly soluble drugs. Aceclofenac is practically in soluble in 
water.  The  dissolution  rate  from  solid  dispersion  was  affected  by  the  carrier 
concentration. PVP and PVA were used as carriers in the preparation of aceclofenac solid 
dispersion in the ratios of 1:1, 1:3 and 1:9 by kneading and solvent evaporation method. 
Procedure for preparation of aceclofenac solid dispersion by kneading method:
PVP or  PVA and solvent  were  mixed  together  in  a  mortar  so as  to  obtain  a 
homogenous  paste.  Aceclofenac  was  then  added  slowly  with  constant  stirring.  The 
mixture  was then ground for  1  hour.  During this  process,  an  appropriate  quantity  of 
solvent was added to the mixture in order to maintain a suitable consistency. The paste 
was dried in oven at 40°C for 24 hours. The dried complex was pulverized into a fine 
power. 
Procedure for preparation of aceclofenac solid dispersion by solvent evaporation 
method 
In solvent evaporation method, ethanol was used as solvent and three different 
drug: carrier ratios were used (1:1, 1:3, 1:9) to prepare solid dispersion of aceclofenac. 
Respective amount of carrier was dissolved in required amount of ethanol taken in 
a  conical  flask  to  get  a  clear  completely  soluble  polymer  ethanol  solution.  Magnetic 
stirrer was used for this purpose. The weighed amount of aceclofenac was added to this 
solution  carefully  with  constant  stirring.  Stirring  was  continued  until  the  drug  was 
completely incorporated in solvent. Then the solvent was removed by evaporation at 40° 
C under vacuum. The mass obtained was dried crushed, pulverized and shifted through 
mesh no. 80.
Physical mixture (PM)
Drug: Carrier ratio of 1:1 was used to prepare physical mixture (1000mg of drug 
and 1000mg of carrier). The drug and carrier were mixed thoroughly in a mortar. This 
was done by geometric dilution technique to ensure homogenous distribution.
Table .8 Drug carrier ratio and respective amount taken:
CHARACTERIZATION AND EVALUATION OF ACECLOFENAC SOLID 
DISPERSION
a. Thin layer Chromatography 
b. IR spectral Analysis 
c. Powdered  X-ray Diffraction studies
d. Differential Scanning Calorimetry 
e. Drug content uniformity
f.  Invitro dissolution studies 
Thin layer chromatography (TLC):
A thin layer chromatographic method was also carried to study the interaction 
between the drug and carriers and also to confirm the chemical satiability of the solid 
dispersions  prepared.  For  this,  the pure drug and the solid  dispersions  prepared  with 
various  carriers  by  solvent  evaporation  method  were  subjected  to  chromatographic 
studies. 
The TLC system used for this study is given below.
Precoated TLC Plates :  Manufactured by SD Fine chemicals Ltd, Mumbai
Adsorbent Layer : Silicagel GF 254.
Layer Thickness : 250 &µm.
Separation technique : Ascending
Chamber Saturation : The chamber was lined on three sides with filter paper and 
saturated for 30 minutes.       
Mobile phase : Toluene: ethyl acetate: glacial acid [5:5:0.2% v/v]
Preparation of sample :  A  suitable  amount  of  pure  drug  or  equivalent  solid    
  dispersion dissolved in ethanol and used for spotting.
Amount applied : 10 µl. 
Detection : Short and long wavelength of light. 
The Rf values obtained were given in the table.9-10 and thin layer chromatograms 
of various solid dispersions were shown in fig.3-4. 
References
Table. 9 TLC data for various solid dispersions systems (Kneading Method)
Solid 
dispersion 
ratio
Aceclofenac 
PVP10
Aceclofenac 
PVP40
Aceclofenac 
PVP360
Aceclofenac 
PVP10 
PVA8136
Aceclofenac 
PVP40 
PVA8136
Aceclofenac 
PVP 360 
PVA8136
Pure drug 2.04 2.12 2.13 2.00 2.13 2.00
1:1 2.04 2.01 2.04 2.00 2.08 2.04
1:3 2.04 2.02 2.02 2.00 2.10 2.00
1:9 2.04 2.12 2.02 2.00 2.10 2.00
Table. 10 TLC data for various solid dispersions systems (Solvent Evaporation method)
Solid 
dispersion 
ratio
Aceclofenac 
PVP10
Aceclofenac 
PVP40
Aceclofenac 
PVP360
Aceclofenac 
PVP10 
PVA8136
Aceclofenac 
PVP40 
PVA8136
Aceclofenac
PVP 360
PVA8136
Pure drug 2.00 2.09 2.04 2.08 2.00 2.04
1:1 2.09 2.09 2.04 2.00 2.00 2.04
1:3 2.09 2.09 2.10 2.08 2.00 2.04
1:9 2.09 2.10 2.10 2.08 2.00 2.04
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KM PVP 10
KM PVP 40
KM PVP360
KM PVP 10 
+PVA 8136
KM PVP40 + 
PVA8136
KM PVP360 
+PVA 8136
Fig.3 Thin layer chromatogram of various solid dispersions
(Kneading method)
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SE PVP10
SEPVP 40
SE PVP360
SE PVP10 PVA8136
SE PVP 40 PVA8136
SE PVP360 PVA 
8136
Fig.4 Thin layer chromatogram of various solid dispersions 
(solvent evaporation method)
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IR Spectral analysis:
Fourier  Transform (FTIR)  spectra  of  the  samples  were obtained in  the 
range  of  400-4000  cm-1 using  a  Jasco-FT-IR  8201  PC  Spectrophotometer 
(Jasco.Essex) by the KBr disc method. The IR Spectra obtained are given in fig. 
5-7.
 
51
Figure 5: IR spectrum of pure aceclofenac 
Figure 6: IR spectrum of solid dispersions of aceclofenac with PVP 40 (1:9) KM
Figure 6: IR spectrum of solid dispersions of aceclofenac with PVP 40 (1:9) SE
Powder X-ray diffractometry:
The Powder X-ray Diffraction  Patterns  were recorded using a siemens, 
Munich,  Germany)  with  Cu  as  anode  material  and  crystal  graphite 
monochromator, operated at a voltage of 40 KV and a current of 30 MA. The 
samples  were  analyzed  in  the  2θ  angle  range  of  2° to  65° and  the  process 
parameters  were set  as  follows:  step  size  of  0.45° (2θ),  scan step  time of  0.5 
seconds and time of acquisition of 2 hours. The results were shown in fig. 8, 9.
Figure 8 X- ray diffraction studies of pure aceclofenac: 
Figure9 X- ray diffraction studies of solid dispersions of 
aceclofenac with PVP 40 (1:9) KM
Differential Scanning Calorimetry:
The DSC measurements  were performed using a Mettleer  Toledo DSC 
821e DSC module  controlled  by  STARe Software  (Mettler  –  Toledo.  GmbH, 
Switzerland).  All  accurately  weighted  samples  (1  mg  of  aceclofenac  or  its 
equivalent) were placed in seated aluminum pans, before heating under nitrogen 
flow (20ml/min) at a scanning rate of 10° C min-1, over the temperature range of 
30°C to 220°C. An empty aluminum pan was used as reference. 
The  samples  were  analyzed  for  aceclofenac  after  suitable  dilution  by 
measuring  absorbance  at  365  nm  using  Jasco  V-530  UV  visible 
spectrophotometer. Phosphate buffer of pH 7.4 used as blank. The percentage of 
aceclofenac dissolved at various time intervals was calculated and plotted against 
time.  T50,  T90 values  calculated  from these  dissolution  curves.  The  results  are 
shown in fig.10-11.
Figure 10 DSC thermogram of pure aceclofenac
Figure 11: DSC thermogram of solid dispersion of aceclofenac with PVP 40 (1:9) KM
Drug content uniformity 
The  prepared  aceclofenac  solid  dispersion  was  tested  for  drug  content 
uniformity.  From  each  batch  of  solid  dispersion  prepared  in  different  ratios, 
equivalent to 100mg of aceclofenac solid dispersion were taken and analyzed for 
drug content uniformity. 
Estimation of aceclofenac in solid dispersion by UV Spectroscopy:   
Accurately weighed amount of solid dispersion was dissolved in 100 ml of 
pH 7.4 phosphate buffer in 100ml volumetric flask which was previously clean 
and dry. This solution after suitable dilution was measured for absorbance at 273 
nm in a Jasco V530 UV visible spectrophotometer.  The results were shown in 
table.11, 12. 
Table.11 Drug content uniformity in solid dispersions (Kneading 
method)
Solid 
dispersion
Drug : 
carrier
Amount of 
SD taken
Expected 
amount of 
aceclofenac 
in SD (mg)
Aceclofenac 
estimated by 
spectrophotomete
r (%)
Aceclofenac 
PVP10
1:1 200 100 96.3
1:3 400 100 97.8
1:9 1000 100 96.0
Aceclofenac 
PVP40
1:1 200 100 96.3
1:3 400 100 93.6
1:9 1000 100 96.3
Aceclofenac 
PVP360
1:1 200 100 99.0
1:3 400 100 94.8
1:9 1000 100 97.2
Aceclofenac 
PVP10 
PVA8136
1:1 200 100 94.2
1:3 400 100 99.0
1:9 1000 100 97.2
Aceclofenac 
PVP 40 
PVA8136
1:1 200 100 101.4
1:3 400 100 100.2
1:9 1000 100 99.6
Aceclofenac 
PVP360 
PVA8136
1:1 200 100 101.4
1:3 400 100 99.6
1:9 1000 100 99.9
Table.12  Drug  content  uniformity  in  solid  dispersions  (Solvent 
evaporation method)
Solid 
dispersion
Drug : 
carrier
Amount of 
SD taken
Expected 
amount of 
aceclofenac 
in SD (mg)
Aceclofenac 
estimated by 
spectrophotometer 
(%)
Aceclofenac 
PVP10
1:1 200 100 94.5
1:3 400 100 92.4
1:9 1000 100 93.6
Aceclofenac 
PVP40
1:1 200 100 90.6
1:3 400 100 94.5
1:9 1000 100 95.4
Aceclofenac 
PVP360
1:1 200 100 99.3
1:3 400 100 93.0
1:9 1000 100 97.2
Aceclofenac 
PVP10 
PVA8136
1:1 200 100 99.0
1:3 400 100 92.4
1:9 1000 100 100.2
Aceclofenac 
PVP140 
PVA8136
1:1 200 100 94.5
1:3 400 100 92.4
1:9 1000 100 93.6
Aceclofenac 
PVP360 
PVA8136
1:1 200 100 94.5
1:3 400 100 96.3
1:9 1000 100 97.8
Invitro dissolution studies:
The dissolution studies are the most important part of the evaluation of 
solid dispersion, where the dissolution of pure drug and solid dispersion is carried 
out.  Dissolution  rate  studies  of  various  solid  dispersions  were  carried  out  in 
phosphate buffer of PH 7.4 using USP XXII dissolution apparatus (Electro lab).
Dissolution method: 
900ml of phosphate buffer of PH 7.4 was used as dissolution medium. SDs 
equivalent  to  100mg  of  aceclofenac  was  taken  in  a  hard  gelatin  capsule;  a 
stainless steel wire was wound around the capsule to sink. The paddle type stirrer 
was adjusted to 75 rpm. The temperature was maintained at 37°±2°c. 5 ml aliquot 
dissolution  media  was  withdrawn  at  different  time  intervals  and  volume 
withdrawn was replaced with fresh quantity of dissolution medium. The samples 
were analyzed for aceclofenac after suitable dilution by measuring the absorption 
values at 273 nm using Jasco V 530 UV visible spectrophotometer.  Phosphate 
buffer  of pH 7.4 used as  a blank.  The percentage  of aceclofenac  dissolved at 
various time intervals was calculated and plotted against time. T50, T90 values were 
calculated from these dissolution curves. The results are shown in table.13-24 and 
fig. 13-24.  
Figure: 12 Dissolution apparatus (Electrolab)
Table.13 Dissolutiion profile of aceclofenac from PVP 10 solid 
dispersion at different drug carreir ratios (kneading method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 18.9 17.55 35.1
30 4.5 10.35 54.9 45.9 45.0
45 10.2 22.5 70.2 56.7 54.9
60 15.75 36.0 73.3 63.0 54.9
75 21.6 48.6 76.5 72.0 63.0
90 23.4 54.9 76.5 72.0 82.8
105 24.2 62.1 77.4 73.35 91.8
120 25.4 62.1 77.4 73.35 91.8
Figure 13 Dissolutiion profile of aceclofenac from PVP 10 solid 
dispersion at different drug carreir ratios (kneading method)
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Table.14 Dissolution profile of aceclofenac from PVP 40 solid 
dispersion at different drug carrier ratios (kneading method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 20.7 9.0 20.7
30 4.5 10.35 67.0 31.5 54.9
45 10.2 22.5 72.0 45.9 68.4
60 15.75 36.0 77.4 45.9 72.0
75 21.6 48.6 78.3 49.5 72.0
90 23.4 54.9 80.5 51.3 91.8
105 24.2 62.1 85.5 51.3 93.7
120 25.4 62.1 85.5 51.3 93.7
Figure 14 Dissolution profile of aceclofenac from PVP 40 solid 
dispersion at different drug carrier ratios (kneading method)
0
10
20
30
40
50
60
70
80
90
100
1
Time in minutes
Pe
rc
en
ta
ge
 o
f a
ce
cl
of
en
ac
 re
le
as
ed
Pure Drug PM SD 1:1 SD 1:3 SD 1:9
Table.15 Dissolution profile  of  aceclofenac  from PVP 360 solid 
dispersion at different drug carrier ratios (kneading method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 20.7 18.9 1.8
30 4.5 10.35 54.9 53.1 10.8
45 10.2 22.5 68.4 63.9 52.2
60 15.75 36.0 72.0 68.4 52.2
75 21.6 48.6 72.0 68.4 68.4
90 23.4 54.9 91.8 70.2 68.4
105 24.2 62.1 91.8 70.2 82.8
120 25.4 62.1 91.8 72.0 95.4
Figure 15 Dissolution profile of aceclofenac from PVP 360 solid 
dispersion at different drug carrier ratios (kneading method)
0
10
20
30
40
50
60
70
80
90
100
1
Time in minutes
Pe
rc
en
ta
ge
 o
f a
ce
lc
of
en
ac
 re
le
as
ed
Pure Drug PM SD 1:1 SD 1:3 SD 1:9
Table.16  Dissolution  profile  of  aceclofenac  from PVP 10;  PVA 
8136 solid dispersion at  different  drug carrier  ratios  (kneading 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 10.8 9.0 7.2
30 4.5 10.35 34.6 9.0 18.6
45 10.2 22.5 58.5 20.7 35.1
60 15.75 36.0 62.1 37.8 50.4
75 21.6 48.6 68.4 50.4 68.4
90 23.4 54.9 72.0 54.9 75.6
105 24.2 62.1 76.5 58.5 75.6
120 25.4 62.1 81.9 75.6 79.2
Figure 16 Dissolution profile of aceclofenac from PVP 10; PVA 
8136 solid dispersion at different drug carrier ratios (kneading 
method)
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Table.17  Dissolution  profile  of  aceclofenac  from PVP 40;  PVA 
8136 solid dispersion at  different  drug carrier  ratios  (kneading 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 15.3 4.5 18.0
30 4.5 10.35 49.5 11.7 45.0
45 10.2 22.5 62.1 39.6 58.5
60 15.75 36.0 63.0 54.9 68.4
75 21.6 48.6 63.0 66.6 78.3
90 23.4 54.9 64.8 81.9 82.8
105 24.2 62.1 64.8 84.6 82.8
120 25.4 62.1 64.8 86.4 82.8
Figure 17 Dissolution profile of aceclofenac from PVP 40; PVA 
8136 solid dispersion at different drug carrier ratios (kneading 
method)
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Table.18 Dissolution profile of aceclofenac from PVP 360; PVA 
8136 solid dispersion at  different  drug carrier  ratios  (kneading 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 18.9 13.95 14.4
30 4.5 10.35 53.1 26.1 27.0
45 10.2 22.5 63.9 36.0 50.4
60 15.75 36.0 68.4 43.2 58.5
75 21.6 48.6 68.4 55.8 63.0
90 23.4 54.9 70.2 58.5 68.4
105 24.2 62.1 70.2 64.8 68.4
120 25.4 62.1 72.0 66.6 68.4
Figure 18 Dissolution profile of aceclofenac from PVP 360; PVA 
8136 solid dispersion at different drug carrier ratios (kneading 
method)
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Table.19  Dissolution  profile  of  aceclofenac  from  PVP  10  solid 
dispersion  at  different  drug  carrier  ratios  (solvent  evaporation 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 16.2 7.2 25.2
30 4.5 10.35 45.9 13.9 56.7
45 10.2 22.5 55.8 49.5 63.9
60 15.75 36.0 65.7 56.7 70.2
75 21.6 48.6 66.6 62.1 73.3
90 23.4 54.9 67.5 62.1 73.3
105 24.2 62.1 68.4 64.8 75.6
120 25.4 62.1 76.45 67.0 75.6
Figure 19  Dissolution profile  of  aceclofenac from PVP 10 solid 
dispersion  at  different  drug  carrier  ratios  (solvent  evaporation 
method)
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Table.20  Dissolution  profile  of  aceclofenac  from  PVP  40  solid 
dispersion  at  different  drug  carrier  ratios  (solvent  evaporation 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 7.2 5.85 18.0
30 4.5 10.35 14.4 17.55 31.5
45 10.2 22.5 33.3 22.5 37.8
60 15.75 36.0 46.3 63.0 52.2
75 21.6 48.6 56.7 67.95 54.9
90 23.4 54.9 61.2 67.95 54.9
105 24.2 62.1 65.7 71.1 58.5
120 25.4 62.1 67.5 71.1 58.5
Figure 20 Dissolution profile of aceclofenac from PVP 40 solid 
dispersion at different drug carrier ratios (solvent evaporation 
method)
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Table.21 Dissolution profile  of  aceclofenac from PVP 360 solid 
dispersion  at  different  drug  carrier  ratios  (solvent  evaporation 
method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 13.5 5.85 3.6
30 4.5 10.35 53.1 29.25 18.0
45 10.2 22.5 61.65 40.95 18.0
60 15.75 36.0 70.2 53.1 35.0
75 21.6 48.6 75.6 62.1 45.0
90 23.4 54.9 79.2 64.8 45.0
105 24.2 62.1 81.0 66.6 50.4
120 25.4 62.1 81.9 71.1 57.6
Figure 21 Dissolution profile of aceclofenac from PVP 360 solid 
dispersion at different drug carrier ratios 
(solvent evaporation method)
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Table.22 Dissolution profile of aceclofenac from PVP 10; pva8136 
solid  dispersion  at  different  drug  carrier  ratios  (solvent 
evaporation method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 12.6 12.6 10.8
30 4.5 10.35 33.5 29.2 14.4
45 10.2 22.5 41.4 49.5 27.9
60 15.75 36.0 58.5 58.5 45.0
75 21.6 48.6 61.2 64.8 63.0
90 23.4 54.9 67.5 68.4 68.4
105 24.2 62.1 68.4 68.4 75.6
120 25.4 62.1 72.0 70.2 75.6
Figure 22 Dissolution profile of aceclofenac from PVP 10; 
PVA8136 solid dispersion at different drug carrier ratios (solvent 
evaporation method)
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Table.23  Dissolution  profile  of  aceclofenac  from  PVP  40; 
PVA8136 solid dispersion at different drug carrier ratios (solvent 
evaporation method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 7.2 1.8 9.0
30 4.5 10.35 26.1 5.4 9.0
45 10.2 22.5 41.4 13.95 20.7
60 15.75 36.0 47.7 26.1 37.8
75 21.6 48.6 54.9 32.4 50.4
90 23.4 54.9 58.5 36.6 54.9
105 24.2 62.1 64.8 43.2 58.5
120 25.4 62.1 64.8 45.0 75.6
Figure 23 Dissolution profile of aceclofenac from PVP 40; 
PVA8136 solid dispersion at different drug carrier ratios (solvent 
evaporation method)
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Table.24  Dissolution  profile  of  aceclofenac  from  PVP  360; 
PVA8136 solid dispersion at different drug carrier ratios (solvent 
evaporation method)
Time in 
minutes
Percentage release of aceclofenac from different drug carrier 
ratios
Pure drug 
100 mg
Physical 
mixture
1:1 1:3 1:9
0 0 0 0 0 0
15 2.6 5.4 17.55 7.2 7.2
30 4.5 10.35 34.2 10.8 14.4
45 10.2 22.5 49.5 26.1 28.8
60 15.75 36.0 54.9 26.1 36.0
75 21.6 48.6 56.7 34.2 43.2
90 23.4 54.9 59.4 34.2 43.2
105 24.2 62.1 68.4 41.4 55.8
120 25.4 62.1 68.4 47.7 63.0
Figure 24 Dissolution profile of aceclofenac from PVP 360; 
PVA8136 solid dispersion at different drug carrier ratios (solvent 
evaporation method)
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 Table.25 Dissolution profile of aceclofenac pure form and from 
solid  dispersions  prepared  with  various  carriers  at  1:1  ratio. 
(kneading method)
Time in 
minutes
Percentage  release of aceclofenac from
Pure 
drug 
100 mg
PVP 10 PVP 40
PVP 
360
PVP 
10; 
PVA 
8136
PVP 
40; 
PVA 
8136
PVP 
360; 
PVA 
8136
0 0 0 0 0 0 0 0
15 2.6 18.9 20.7 20.7 10.8 15.3 17.55
30 4.5 54.9 67.0 54.9 34.6 49.5 34.2
45 10.2 70.2 72.0 68.4 58.5 62.1 49.5
60 15.75 73.3 77.4 72.0 62.1 63.0 54.9
75 21.6 76.5 78.3 72.0 68.4 63.0 56.7
90 23.4 76.5 80.5 91.8 72.0 64.8 59.4
105 24.2 77.4 85.5 91.8 76.5 64.8 68.4
120 25.4 77.4 85.5 91.8 81.9 64.8 68.4
Figure 28 Dissolution profile of aceclofenac pure form and from 
solid dispersions prepared with various carriers at 1:1 ratio. 
(kneading method)
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Table.26 Dissolution profile of aceclofenac pure form and from 
solid dispersions prepared with various carriers at 1:3 ratio. 
(kneading method)
Time in 
minute
s
Percentage  release of aceclofenac from
Pure 
drug 
100 
mg
PVP 
10
PVP 
40
PVP 
360
PVP10; 
PVA8136
PVP 40; 
PVA8136
PVP 360; 
PVA8136
0 0 0 0 0 0 0 0
15 2.6 17.55 9.0 18.9 9.0 4.5 13.95
30 4.5 45.9 31.5 53.1 9.0 11.7 26.1
45 10.2 56.7 45.9 63.9 20.7 39.6 36.0
60 15.75 63.0 45.9 68.4 37.8 54.9 43.2
75 21.6 72.0 49.5 68.4 50.4 66.6 55.8
90 23.4 72.0 51.3 70.2 54.9 81.9 58.5
105 24.2 73.35 51.3 70.2 58.5 84.6 64.8
120 25.4 73.35 51.3 72.0 75.6 86.4 66.6
Figure 26 Dissolution profile of aceclofenac pure form and from 
solid dispersions prepared with various carriers at 1:3 ratio. 
(kneading method)
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Table.27 Dissolution profile of  aceclofenac pure form and from 
solid  dispersions  prepared  with  various  carriers  at  1:9  ratio. 
(kneading method)
Time in 
minutes
Percentage  release of aceclofenac from
Pure 
drug 
100 mg
PVP 
10
PVP 
40
PVP 
360
PVP10;
PVA8136
PVP 40; 
PVA8136
PVP360; 
PVA8136
0 0 0 0 0 0 0 0
15 2.6 35.1 20.7 1.8 7.2 18.0 14.4
30 4.5 45.0 54.9 10.8 18.6 45.0 27.0
45 10.2 54.9 68.4 52.2 35.1 58.5 50.4
60 15.75 54.9 72.0 52.2 50.4 68.4 58.5
75 21.6 63.0 72.0 68.4 68.4 78.3 63.0
90 23.4 82.8 91.8 68.4 75.6 82.8 68.4
105 24.2 92.7 93.7 82.8 75.6 82.8 68.4
120 25.4 92.7 93.7 95.4 79.2 82.8 68.4
Figure 27  Table.27 Dissolution profile of aceclofenac pure form 
and from solid dispersions prepared with various carriers at 1:9 
ratio. (kneading method)
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Table.28  Dissolution profile of  aceclofenac pure form and from 
solid  dispersions  prepared  with  various  carriers  at  1:1  ratio. 
(solvent evaporation method)
Time In 
Minutes
Percentage  release of aceclofenac from
Pure 
drug 
100 mg
SD 
with 
PVP 10
SD 
with 
PVP 40
SD 
with 
PVP 
360
SD 
with 
PVP 
10; 
PVA 
8136
SD 
with 
PVP 
40; 
PVA 
8136
SD 
with 
PVP 
360; 
PVA 
8136
0 0 0 0 0 0 0 0
15 2.6 16.2 7.2 13.5 12.6 7.2 17.55
30 4.5 45.9 14.4 53.1 33.5 26.1 34.2
45 10.2 55.8 33.3 61.65 41.4 41.4 49.5
60 15.75 65.7 46.3 70.2 58.5 47.7 54.9
75 21.6 66.6 56.7 75.6 61.2 54.9 56.7
90 23.4 67.5 61.2 79.2 67.5 58.5 59.4
105 24.2 68.4 65.7 81.0 68.4 64.8 68.4
120 25.4 76.45 67.5 81.9 72.0 64.8 68.4
Figure 28 Dissolution profile of aceclofenac pure form and from 
solid dispersions prepared with various carriers at 1:1 ratio. 
(solvent evaporation method)
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Table.29 Dissolution profile of  aceclofenac pure form and from 
solid  dispersions  prepared  with  various  carriers  at  1:3  ratio. 
(solvent evaporation method)
Time In 
Minutes
Percentage  release of aceclofenac from
Pure 
drug 
100 mg
SD 
with 
PVP 10
SD 
with 
PVP 40
SD 
with 
PVP 
360
SD 
with 
PVP 
10; 
PVA 
8136
SD 
with 
PVP 
40; 
PVA 
8136
SD 
with 
PVP 
360; 
PVA 
8136
0 0 0 0 0 0 0 0
15 2.6 7.2 7.2 5.85 12.6 1.8 7.2
30 4.5 13.9 13.9 29.25 29.2 5.4 10.8
45 10.2 49.5 49.5 40.95 49.5 13.95 26.1
60 15.75 56.7 56.7 53.1 58.5 26.1 26.1
75 21.6 62.1 62.1 62.1 64.8 32.4 34.2
90 23.4 62.1 62.1 64.8 68.4 36.6 34.2
105 24.2 64.8 64.8 66.6 68.4 43.2 41.4
120 25.4 67.0 67.0 71.1 70.2 45.0 47.7
Figure 29 Dissolution profile of aceclofenac pure form and from 
solid dispersions prepared with various carriers at 1:3 ratio. 
(solvent evaporation method)
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Table.30 Dissolution profile of aceclofenac pure form and from solid 
dispersions  prepared  with  various  carriers  at  1:9  ratio.  (solvent 
evaporation method)
Time in 
minutes
Percentage  release of aceclofenac from
Pure 
drug 
100 mg
SD 
with 
PVP 10
SD 
with 
PVP 40
SD 
with 
PVP 
360
SD 
with 
PVP 
10; 
PVA 
8136
SD 
with 
PVP 
40; 
PVA 
8136
SD 
with 
PVP 
360; 
PVA 
8136
0 0 0 0 0 0 0 0
15 2.6 25.2 18.0 3.6 10.8 9.0 7.2
30 4.5 56.7 31.5 18.0 14.4 9.0 14.4
45 10.2 63.9 37.8 18.0 27.9 20.7 28.8
60 15.75 70.2 52..2 35.0 45.0 37.8 36.0
75 21.6 73.3 54.9 45.0 63.0 50.4 43.2
90 23.4 73.3 54.9 45.0 68.4 54.9 43.2
105 24.2 75.6 58.5 50.4 75.6 58.5 55.8
120 25.4 75.6 58.5 57.6 75.6 75.6 63.0
Figure 30  Dissolution profile of aceclofenac pure form and from solid 
dispersions  prepared  with  various  carriers  at  1:9  ratio.  (solvent 
evaporation method)
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Table.31  Dissolution  of  aceclofenac  pure  form  and  from  physical 
mixture with various carriers at drug: carrier ratio of 1:1 
Time In 
Minute
s
Percentage aceclofenac dissolved from
Pure 
drug 
100 
mg
PM 
with 
PVP 
10
PM 
with 
PVP 
40
PM 
with 
PVP 
360
PM with 
PVP 10; 
PVA8136
PM with 
PVP 40; 
PVA8136
PM with 
PVP 360; 
PVA8136
0 0 0 0 0 0 0 0
15 2.6 5.4 10.35 9.0 9.0 5.4 10.35
30 4.5 10.35 18.9 9.0 17.55 15.75 24.3
45 10.2 22.5 31.5 31.5 34.2 27.45 34.42
60 15.75 36.0 39.6 34.2 36.0 37.8 37.8
75 21.6 48.6 51.3 43.2 43.2 45.9 39.6
90 23.4 54.9 53.1 51.3 46.35 46.35 40.95
105 24.2 62.1 53.1 53.1 48.6 48.6 48.6
120 25.4 62.1 53.1 53.1 49.5 49.5 48.6
Figure  31  Dissolution  of  aceclofenac  pure  form  and  from  physical 
mixture with various carriers at drug: carrier ratio of 1:1 
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Table No.32 Percentage release of aceclofenac from various solid dispersions (kneading method)
Time in 
minutes
Percentage release of aceclofenac from
Pure 
drug
ACE: PVP10 ACE: PVP40 ACE: PVP360
ACE: 
PVP10,PVA813
6
ACE: 
PVP40,PVA813
6
ACE: 
PVP360,PVA8136
1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15 2.6 18.
9
17.5
5
35.
1
20.
7
9.0 20.
7
20.
7
18.
9
1.8 10.8 9.0 7.2 15.3 4.5 18.0 18.9 13.95 14.4
30 4.5 54.
9
45.9 45.
0
67.
0
31.
5
54.
9
54.
9
53.
1
10.
8
34.6 9.0 18.6 49.5 11.7 45.0 53.1 26.1 27.0
45 10.2 70.
2
56.7 54.
9
72.
0
45.
9
68.
4
68.
4
63.
9
52.
2
58.5 20.7 35.1 62.1 39.6 58.5 63.9 36.0 50.4
60 15.7
5
73.
3
63.0 54.
9
77.
4
45.
9
72.
0
72.
0
68.
4
52.
2
62.1 37.8 50.4 63.0 54.9 68.4 68.4 43.2 58.5
75 21.6 76.
5
72.0 63.
0
78.
3
49.
5
72.
0
72.
0
68.
4
68.
4
68.4 50.4 68.4 63.0 66.6 78.3 68.4 55.8 63.0
90 23.4 76.
5
72.0 82.
8
80.
5
51.
3
91.
8
91.
8
70.
2
68.
4
72.0 54.9 75.6 64.8 81.9 82.8 70.2 58.5 68.4
105 24.2 77.
4
73.3
5
91.
8
85.
5
51.
3
93.
7
91.
8
70.
2
82.
8
76.5 58.5 75.6 64.8 84.6 82.8 70.2 64.8 68.4
120 25.4 77.
4
73.3
5
91.
8
85.
5
51.
3
93.
7
91.
8
72.
0
95.
4
81.9 75.6 79.2 64.8 86.4 82.8 72.0 66.6 68.4
Table No.33 Percentage release of aceclofenac from various solid dispersions (solvent evaporation method)
Time in 
minute
s
Percentage release of aceclofenac from
Pure 
drug
ACE: PVP10 ACE: PVP40 ACE: PVP360
ACE: 
PVP10,PVA813
6
ACE: 
PVP40,PVA8136
ACE: 
PVP360,PVA8136
1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15 2.6 16.2 7.2 25.
2
7.2 5.85 18.0 13.5 5.85 3.6 12.6 12.6 10.8 7.2 1.8 9.0 17.5
5
7.2 7.2
30 4.5 45.9 13.
9
56.
7
14.
4
17.5
5
31.5 53.1 29.2
5
18.
0
33.5 29.2 14.4 26.
1
5.4 9.0 34.2 10.8 14.4
45 10.2 55.8 49.
5
63.
9
33.
3
22.5 37.8 61.6
5
40.9
5
18.
0
41.4 49.5 27.9 41.
4
13.9
5
20.
7
49.5 26.1 28.8
60 15.7
5
65.7 56.
7
70.
2
46.
3
63.0 52..
2
70.2 53.1 35.
0
58.5 58.5 45.0 47.
7
26.1 37.
8
54.9 26.1 36.0
75 21.6 66.6 62.
1
73.
3
56.
7
67.9
5
54.9 75.6 62.1 45.
0
61.2 64.8 63.0 54.
9
32.4 50.
4
56.7 34.2 43.2
90 23.4 67.5 62. 73. 61. 67.9 54.9 79.2 64.8 45. 67.5 68.4 68.4 58. 36.6 54. 59.4 34.2 43.2
1 3 2 5 0 5 9
105 24.2 68.4 64.
8
75.
6
65.
7
71.1 58.5 81.0 66.6 50.
4
68.4 68.4 75.6 64.
8
43.2 58.
5
68.4 41.4 55.8
120 25.4 76.4
5
67.
0
75.
6
67.
5
71.1 58.5 81.9 71.1 57.
6
72.0 70.2 75.6 64.
8
45.0 75.
6
68.4 47.7 63.0
Table.34 Relation between % carrier and T50, T90 values for 
aceclofenac- PVP10 solid dispersions: 
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 27.5 40.5 - -
1 3 40.0 53.0 - -
1 9 40.0 26.5 102.0 -
Table.35 Relation between % carrier and T50, T90 values for 
aceclofenac- PVP 40 solid dispersions: 
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 22.5 66.0 - -
1 3 88.0 47.5 - -
1 9 27.5 57.5 88.5 -
Table.36 Relation between % carrier and T50, T90 values for 
aceclofenac- PVP 360 solid dispersions: 
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 27.5 28.5 88.5 -
1 3 28.5 56.5 - -
1 9 43.0 104.0 113.5 -
Table.37 Relation between % carrier and T50, T90 values for 
aceclofenac- PVP10, PVA8136 solid dispersions
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 38.5 51.5 - -
1 3 74.5 51.5 - -
1 9 59.5 59.5 - -
Table.38 Relation between % carrier and T50, T90 values for 
aceclofenac- PVP 40, PVA 8136 solid dispersions
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 36.5 68.5 - -
1 3 54.5 - - -
1 9 38.5 74.5 - -
Table.39  Relation  between  %  carrier  and  T50,  T90  values  for 
aceclofenac- PVP 360, PVA 8136 solid dispersions
% of drug
%of 
carrier
T50 (min) T90 (min)
KM SE KM SE
1 1 28.0 54.6 - -
1 3 67.0 - - -
1 9 44.5 94.0 - -
Table.40 Percentage aceclofenac undissolved from pure form and 
from  PVP  10  solid  dispersions  at  various  drug  carrier  ratios 
(kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4(1.988)
94.6
(1.975)
81.1
(1.909)
82.45
(1.916)
64.9
(1.812)
30 95.5(1.980)
89.65
(1.952)
45.1
(1.650)
54.1
(1.733)
55.0
(1.740)
45 89.8(1.953)
77.5
(1.889)
29.8
(1.474)
43.3
(1.636)
45.1
(1.654)
60 84.25(1.925)
64.0
(1.806)
26.7
(1.426)
37.0
(1.568)
45.1
(1.654)
75 78.4(1.894)
51.4
(1.710)
23.5
(1.371)
28.0
(1.447)
37.0
(1.568)
90 76.6(1.884)
45.1
(1.654)
23.5
(1.371)
28.0
(1.447)
17.2
(1.235)
105 75.8(1.879)
37.9
(1.578)
22.6
(1.354)
26.65
(1.425)
7.3
(0.863)
120 74.6(1.872)
37.9
(1.578)
22.6
(1.354)
26.65
(1.425)
7.3
(0.863)
Figure 32 Percentage aceclofenac undissolved from pure form and 
from PVP 10 solid dispersions at various drug carrier ratios 
(kneading method)
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Table.41 Percentage aceclofenac undissolved from pure form and 
from PVP 40 solid dispersions at various drug carrier ratios 
(kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4(1.988)
89.65
(1.952)
79.3
(1.899)
87.4
(1.941)
79.3
(1.899)
30 95.5(1.980)
81.1
(1.909)
33.0
(1.518)
65.8
(1.818)
45.1
(1.654)
45 89.8(1.953)
68.5
(1.855)
28.0
(1.447)
48.7
(1.687)
31.6
(1.499)
60 84.25(1.925)
60.4
(1.781)
22.6
(1.354)
43.3
(1.636)
28.0
(1.447)
75 78.4(1.894)
48.7
(1.687)
21.7
(1.336)
31.6
(1.499)
28.0
(1.447)
90 76.6(1.884)
46.9
(1.671)
19.5
(1.290)
29.8
(1.474)
8.2
(0.913)
105 75.8(1.879)
46.9
(1.671)
14.5
(1.161)
29.8
(1.474)
8.2
(0.913)
120 74.6(1.872)
46.9
(1.671)
14.5
(1.161)
28.0
(1.447)
8.2
(0.913)
Figure 33 Percentage aceclofenac undissolved from pure form and 
from PVP 40 solid dispersions at various drug carrier ratios 
(kneading method)
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Table.42 Percentage aceclofenac undissolved from pure form and 
from PVP 360  solid  dispersions  at  various  drug  carrier  ratios 
(kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
91.0
(1.959)
79.3
(1.899)
81.1
(1.909)
98.2
(1.992)
30 95.5
(1.980)
91.0
(1.959)
45.1
(1.654)
46.9
(1.671)
89.2
(1.952)
45 89.8
(1.953)
68.5
(1.835)
31.6
(1.449)
36.1
(1.557)
47.8
(1.679)
60 84.25
(1.925)
65.8
(1.818)
28.0
(1.447)
31.6
(1.499)
47.8
(1.679)
75 78.4
(1.894)
56.8
(1.754)
28.0
(1.447)
31.6
(1.499)
31.6
(1.499)
90 76.6
(1.884)
48.7
(1.687)
8.2
(0.913)
29.8
(1.474)
31.6
(1.499)
105 75.8
(1.879)
46.9
(1.671)
8.2
(0.913)
29.8
(1.474)
17.2
(1.235)
120 74.6
(1.872)
46.9
(1.671)
8.2
(0.913)
28.0
(1.447)
4.6
(0.662)
Figure 34 Percentage aceclofenac undissolved from pure form and from 
PVP 360 solid dispersions at various drug carrier ratios (kneading method)
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Table.43 Percentage aceclofenac undissolved from pure form and 
from PVP 10: PVA 8136 solid dispersions at various drug carrier 
ratios (kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
91.0
(1.959)
89.2
(1.950)
91.0
(1.959)
92.8
(1.967)
30 95.5
(1.980)
82.45
(1.916)
65.4
(1.815)
91.0
(1.959)
81.4
(1.910)
45 89.8
(1.953)
65.8
(1.818)
41.5
(1.618)
79.3
(1.899)
64.9
(1.812)
60 84.25
(1.925)
64.0
(1.806)
37.9
(1.578)
62.2
(1.793)
49.6
(1.695)
75 78.4
(1.894)
56.8
(1.754)
31.6
(1.499)
49.6
(1.695)
31.6
(1.499)
90 76.6
(1.884)
53.65
(1.729)
28.0
(1.447)
45.1
(1.654)
24.4
(1.387)
105 75.8
(1.879)
51.4
(1.710)
23.5
(1.371)
41.5
(1.618)
24.4
(1.387)
120 74.6
(1.872)
50.5
(1.703)
18.1
(1.257)
24.4
(1.387)
20.8
(1.318)
Figure  35  Percentage aceclofenac undissolved from pure form 
and from PVP 10: PVA 8136 solid dispersions at various drug 
carrier ratios (kneading method)
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Table.44 Percentage aceclofenac undissolved from pure form and 
from PVP 40: PVA 8136 solid dispersions at various drug carrier 
ratios (kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
94.6
(1.975)
84.7
(1.927)
95.5
(1.980)
82.0
(1.913)
30 95.5
(1.980)
84.25
(1.925)
50.5
(1.703)
88.3
(1.945)
55.0
(1.740)
45 89.8
(1.953)
72.55
(1.860)
37.9
(1.578)
60.4
(1.781)
41.5
(1.618)
60 84.25
(1.925)
62.2
(1.793)
37.0
(1.568)
45.1
(1.654)
31.6.
(1.499)
75 78.4
(1.894)
54.1
(1.733)
37.0
(1.568)
33.4
(1.523)
21.7
(1.337)
90 76.6
(1.884)
53.65
(1.729)
35.2
(1.546)
18.1
(1.257)
17.2
(1.235)
105 75.8
(1.879)
51.4
(1.710)
35.2
(1.546)
15.4
(1.187)
17.2
(1.235)
120 74.6
(1.872)
50.5
(1.703)
35.2
(1.546)
13.6
(1.133)
17.2
(1.235)
Figure 36 Percentage aceclofenac undissolved from pure form and 
from PVP 40: PVA 8136 solid dispersions at various drug carrier 
ratios (kneading method)
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Table.45 Percentage aceclofenac undissolved from pure form and 
from PVP 360: PVA 8136 solid dispersions at various drug carrier 
ratios (kneading method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
89.65
(1.952)
81.1
(1.909)
86.05
(1.934)
85.6
(1.932)
30 95.5
(1.980)
75.7
(1.879)
46.9
(1.671)
73.9
(1.818)
73.0
(1.863)
45 89.8
(1.953)
65.58
(1.816)
36.1
(1.557)
64.0
(1.806)
49.6
(1.695)
60 84.25
(1.925)
62.2
(1.793)
31.6
(1.499)
56.8
(1.754)
41.5
(1.618)
75 78.4
(1.894)
60.4
(1.781)
31.6
(1.499)
44.2
(1.645)
37.0
(1.568)
90 76.6
(1.884)
59.65
(1.771)
29.8
(1.474)
41.5
(1.618)
31.6
(1.499)
105 75.8
(1.879)
51.4
(1.710)
29.8
(1.474)
35.2
(1.546)
31.6
(1.499)
120 74.6
(1.872)
51.4
(1.710)
28.0
(1.447)
33.4
(1.523)
31.6
(1.499)
Figure 37 Percentage aceclofenac undissolved from pure form and 
from PVP 360: PVA 8136 solid dispersions at various drug carrier 
ratios (kneading method)
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Table.46 Percentage aceclofenac undissolved from pure form and 
from  PVP  10  solid  dispersions  at  various  drug  carrier  ratios 
(solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
94.6
(1.975)
83.8
(1.923)
92.8
(1.967)
74.8
(1.873)
30 95.5
(1.980)
89.65
(1.952)
54.1
(1.733)
86.1
(1.935)
43.3
(1.636)
45 89.8
(1.953)
77.5
(1.889)
44.2
(1.645)
50.5
(1.703)
36.1
(1.557)
60 84.25
(1.925)
64.0
(1.806)
34.3
(1.535)
43.3
(1.636)
29.8
(1.474)
75 78.4
(1.894)
51.4
(1.710)
33.4
(1.523)
37.9
(1.578)
26.7
(1.426)
90 76.6
(1.884)
45.1
(1.654)
32.5
(1.511)
37.9
(1.578)
26.7
(1.426)
105 75.8
(1.879)
37.9
(1.578)
31.5
(1.498)
35.2
(1.546)
24.4
(1.387)
120 74.6
(1.872)
37.9
(1.578)
23.5
(1.371)
33.0
(1.518)
24.4
(1.387)
Figure 38 Percentage aceclofenac undissolved from pure form and 
from  PVP  10  solid  dispersions  at  various  drug  carrier  ratios 
(solvent evaporation method)
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Table.47 Percentage aceclofenac undissolved from pure form and 
from  PVP  40  solid  dispersions  at  various  drug  carrier  ratios 
(solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
89.65
(1.952)
92.8
(1.967)
94.15
(1.973)
82.0
(1.913)
30 95.5
(1.980)
81.1
(1.909)
85.6
(1.932)
82.45
(1.916)
68.5
(1.835)
45 89.8
(1.953)
68.5
(1.855)
66.7
(1.824)
77.5
(1.889)
62.2
(1.793)
60 84.25
(1.925)
60.4
(1.781)
53.7
(1.729)
37.0
(1.568)
47.8
(1.679)
75 78.4
(1.894)
48.7
(1.687)
43.3
(1.636)
32.05
(1.505)
45.1
(1.654)
90 76.6
(1.884)
46.9
(1.671)
38.8
(1.588)
32.05
(1.505)
45.1
(1.654)
105 75.8
(1.879)
46.9
(1.671)
34.3
(1.535)
28.9
(1.460)
41.5
(1.618)
120 74.6
(1.872)
46.9
(1.671)
32.5
(1.511)
28.9
(1.460)
41.5
(1.618)
Figure 39 Percentage aceclofenac undissolved from pure form and 
from PVP 40 solid dispersions at various drug carrier ratios 
(solvent evaporation method)
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Table.48 Percentage aceclofenac undissolved from pure form and 
from PVP 360 solid dispersions at various drug carrier ratios 
(solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 0 0 0 0 0
15 97.4
(1.988)
91.0
(1.959)
86.5
(1.937)
94.15
(1.973)
96.4
(1.984)
30 95.5
(1.980)
91.0
(1.959)
46.9
(1.671)
70.75
(1.849)
82.0
(1.913)
45 89.8
(1.953)
68.5
(1.835)
38.35
(1.583)
59.05
(1.771)
82.0
(1.913)
60 84.25
(1.925)
65.8
(1.818)
29.8
(1.474)
46.9
(1.671)
65.0
(1.812)
75 78.4
(1.894)
56.8
(1.754)
24.4
(1.387)
37.9
(1.578)
55.0
(1.740)
90 76.6
(1.884)
48.7
(1.687)
20.8
(1.318)
35.2
(1.546)
55.0
(1.740)
105 75.8
(1.879)
46.9
(1.671)
19.0
(1.278)
33.4
(1.523)
49.6
(1.695)
120 74.6
(1.872)
46.9
(1.671)
18.1
(1.257)
28.9
(1.460)
42.4
(1.627)
Figure 40 Percentage aceclofenac undissolved from pure form and 
from PVP 360 solid dispersions at various drug carrier ratios 
(solvent evaporation method)
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Table.49 Percentage aceclofenac undissolved from pure form and 
from PVP 10: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
91.0
(1.959)
87.4
(1.941)
87.4
(1.941)
89.2
(1.950)
30 95.5
(1.980)
82.45
(1.916)
66.5
(1.822)
70.8
(1.850)
85.6
(1.932)
45 89.8
(1.953)
65.8
(1.818)
58.6
(1.767)
50.5
(1.703)
72.1
(1.857)
60 84.25
(1.925)
64.0
(1.806)
41.5
(1.618)
41.5
(1.618)
55.0
(1.740)
75 78.4
(1.894)
56.8
(1.754)
38.8
(1.588)
35.2
(1.546)
37.0
(1.568)
90 76.6
(1.884)
53.65
(1.729)
32.5
(1.511)
31.6
(1.499)
31.6
(1.499)
105 75.8
(1.879)
51.4
(1.710)
31.6
(1.499)
31.6
(1.499)
24.4
(1.387)
120 74.6
(1.872)
50.5
(1.703)
28.0
(1.447)
29.8
(1.474)
24.4
(1.387)
Figure41 Percentage aceclofenac undissolved from pure form and 
from PVP 10: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
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Table.50 Percentage aceclofenac undissolved from pure form and 
from PVP 40: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4
(1.988)
94.6
(1.975)
92.8
(1.967)
98.2
(1.992)
91.0
(1.959)
30 95.5
(1.980)
84.25
(1.925)
73.9
(1.868)
94.6
(1.975)
91.0
(1.959)
45 89.8
(1.953)
72.55
(1.860)
58.6
(1.767)
86.05
(1.934)
79.0
(1.899)
60 84.25
(1.925)
62.2
(1.793)
52.3
(1.718)
73.9
(1.868)
62.2
(1.793)
75 78.4
(1.894)
54.1
(1.733)
45.1
(1.654)
67.6
(1.829)
49.6
(1.695)
90 76.6
(1.884)
53.65
(1.729)
41.5
(1.618)
63.4
(1.802)
45.1
(1.654)
105 75.8
(1.879)
51.4
(1.710)
35.2
(1.546)
56.8
(1.754)
41.5
(1.618)
120 74.6
(1.872)
50.5
(1.703)
35.2
(1.546)
55.0
(1.740)
24.4
(1.387)
Figure42  Percentage aceclofenac undissolved from pure form and 
from PVP 40: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
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Table.51 Percentage aceclofenac undissolved from pure form and 
from PVP 360: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
Time in 
minutes
Percentage aceclofenac undissolved from ( log percentage 
aceclofenac undissolved )
Pure drug 100 
mg PM 1:1 1:1 1:3 1:9
0 100(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
100
(2.0)
15 97.4(1.988)
89.65
(1.952)
82.45
(1.916)
92.8
(1.967)
92.8
(1.967)
30 95.5(1.980)
75.7
(1.879)
65.8
(1.818)
89.2
(1.950)
85.6
(1.932)
45 89.8(1.953)
65.58
(1.816)
50.5
(1.703)
73.9
(1.868)
71.2
(1.852)
60 84.25(1.925)
62.2
(1.793)
45.1
(1.654)
73.9
(1.868)
64.0
(1.806)
75 78.4(1.894)
60.4
(1.781)
43.3
(1.636)
65.8
(1.818)
56.8
(1.754)
90 76.6(1.884)
59.65
(1.771)
40.6
(1.608)
65.8
(1.818)
56.8
(1.754)
105 75.8(1.879)
51.4
(1.710)
31.6
(1.499)
58.6
(1.767)
44.2
(1.645)
120 74.6(1.872)
51.4
(1.710)
31.6
(1.499)
52.3
(1.718)
37.0
(1.568tit)
Figure 43 Percentage aceclofenac undissolved from pure form and 
from PVP 360: PVA 8136 solid dispersions at various drug carrier 
ratios (solvent evaporation method)
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Table.52 First order rate constant for aceclofenac dissolution 
from various solid dispersions
Sample K (min-1)
KM SE
Pure drug 0.002149
PM 0.003560
ACE: PVP 10
1:1 0.00198 0.00176
1:3 0.00256 0.00201
1:9 0.00312 0.00299
ACE: PVP 40
1:1 0.02971 0.02561
1:3 0.04286 0.0486
1:9 0.05460 0.0500
ACE: PVP 360
1:1 0.0346 0.02986
1:3 0.04201 0.0486
1:9 0.0501 0.0520
ACE: PVP 10, PVA 8136
1:1 0.00616 0.0046
1:3 0.00677 0.00561
1:9 0.005757 0.00617
ACE: PVP 40, PVA 8136
1:1 0.0040 0.00365
1:3 0.00307 0.00402
1:9 0.00523 0.00468
ACE: PVP 360, PVA 8136
1:1 0.00405 0.002351
1:3 0.00616 0.00623
1:9 0.00677 0.00587
RESULTS AND DISCUSSION
Solid  dispersion  of  aceclofenac  were  prepared  by  depositing   on  the 
polymers namely PVP10, PVP40, PVP360 and PVA 8136 by solvent evaporation 
method and kneading method. Solid dispersions at drug: carrier ratios (1:1, 1:3, 
1:9) were prepared and summarized in table no.8 all solid dispersions prepared 
were found to be fine and free flowing powders. The percent of drug content in 
the solid dispersions were given in table .11, 12. there was no significant loss of 
drug during the preparation of solid dispersions and the proportion of drug and 
carrier remained the same as that initially taken. The estimated drug content of the 
prepared solid dispersions was in the range of 100±8%. 
The prepare solid dispersions were characterized  by TLC, FTIR, X-ray 
diffraction and Differential Scanning Calorimetry   
Thin Layer Chromatography
In TLC studies, aceclofenac dispersed in various carriers showed the same 
Rf value as pure compound and no additional spots were detected. TLC studies 
thus  indicated  no  interaction  between  aceclofenac  and  carriers  in  the  solid 
dispersions  prepared.  This  observation  also indicated  that  aceclofenac  was not 
decomposed during the preparation of solid dispersions.
FT-IR Spectral Analysis
Compatibility studies of aceclofenac and the carriers PVP and PVA were 
carried  out  by  using  FT-IR.  The  IR spectra  obtained  are  given  in  fig.3-5.  In 
aceclofenac  IR  spectrum,  intense  peaks  were  noticed  at  2935.13  cm-1 (–CH2 
stretching),  2717.21  cm-1 (–OH  stretching),  1718.26  cm-1 (–C=O  stretching), 
1585.2 cm-1 (aro.ring stretching) and 1348 cm-1 (–NH stretching).
IR  spectra  of  aceclofenac  and  its  solid  dispersions  are  identical.  The 
principal IR absorption peaks of aceclofenac were all observed in the spectra of 
aceclofenac as well as its dispersions. IR spectra indicated no interaction between 
aceclofenac and carriers in the solid dispersions.
Powder X- Ray Diffraction 
X-ray diffraction studies indicated the presence of celecoxib in amorphous 
form in solid dispersion fig.8-9.  Thus increased dissolution rate in the case of 
solid dispersions may be due to molecular dispersion of the drug in the amorphous 
form through the carriers.
Differential Scanning Calorimetry   
The thermal behavior of aceclofenac-PVP 40 solid dispersion was studied 
using  DSC to  confirm  the  form formations  of  solid  complexes  are  shown in 
fig.10-11.  The  DSC  thermogram  of  exhibited  an  endothermic  peak  at  149ºC 
corresponding to its melting point, hence no polymorphs of aceclofenac could be 
found. For the solid dispersion system, this peak at 136ºC is very small; this result 
can  be  explained  on  the  basis  of  major  interaction  between  the  polymer  and 
aceclofenac.  Furthermore  the  characteristic  endothermic  effect  of  PVP  40  is 
slightly shifted to lower temperature, indicating that aceclofenac has complexed 
with  PVP  40.  This  phenomenon  is  indicative  of  stronger  interaction  between 
aceclofenac and PVP 40 in the solid state 
Dissolution Studies 
The dissolution profiles of pure drug, physical mixture and various solid 
dispersions were given in table .13-24 and fig. 13-24. The dissolution parameters 
of T50 and dissolution rate indicates rapid dissolution of aceclofenac from the solid 
dispersions  when  compared  with  the  pure  drug   and  physical  mixture  as  the 
proportion of the polymer in the dispersion was increased the dissolution rate of 
aceclofenac also increased. T50 values were found to be decreased and K values 
found to be increased when the carrier concentration was raised indicating the fast 
dissolution  of  aceclofenac  at  higher  carrier  concentration.  Among  the  solid 
dispersions  prepared  aceclofenac-PVP40  (1:9)  dispersions  gave  the  highest 
dissolution rate. 
The order of dissolution of aceclofenac from various carriers is 
PVP 360(KM)>PVP40 (KM)> PVP10 (KM)> PVP40,  PVA 8136 (KM)> PVP10, 
PVA8136 (KM), PVP360 (SE)> PVP10 (SE)> PVP10, PVA 8136 (SE), PVP40, 
PVA 8136 (SE)> PVP360, PVA 8136 (KM)> PVP40 (SE)> PVP360, PVA 8136 
(SE).
FORMULATION STUDIES ON SELECTED SOLID 
DISPERSION OF ACECLOFENAC
Tablets may be defined as solid pharmaceutical dosage forms containing 
drug substance with or without suitable diluents, prepared by either compression 
or molding.
Advantages:
• They are unit dosage forms and offer the greatest capabilities of all oral 
dosage  forms  for  the  greatest  dose  precision  and  the  least  content 
variability.
• Their cost is lowest of all oral dosage forms.
• They are the lightest and most compact of all oral dosage forms.
• They lend themselves to certain special release profile products, such as 
enteric or delayed release products.
• They are better suited to large scale production than other unit oral dosage 
forms.
Disadvantages:
• Some  drugs  resist  compression  into  dense  compact,  owing  to  their 
flocculent, low density characters.
• Bitter  tasting drugs, drugs with an objectionable odor or drugs that are 
sensitive to oxygen or atmospheric moisture may require encapsulation or 
the tableting may require coating.
• Drugs with large dose may be difficult  or impossible  to formulate  and 
manufacture as a tablet.   
Formulation of tablets
Aceclofenac solid dispersion in PVP40 at a drug carrier ratio of 1:9 were 
formulated  into  tablets  with  usual  additives  and  evaluated  for  drug  release 
characteristics. Tablets containing 50 mg of aceclofenac were prepared using the 
solid dispersions and other additives as per the formula given in table 55.
Table.53 Formula of tablet formulation:
S.No Ingredients Formulations (mgs)F1 F2
1 Aceclofenac 50
2 Aceclofenac –PVP 40 (1:9) (KM) - 500
3 Lactose 25 25
4 Micro crystalline cellulose 465 15
5 Talc 5 5
6 Magnesium stearate 5 5
Table.54 Materials used for tablet formulation:
Name of the materials Name of company
Aceclofenac: PVP40 (1:9) 
drug carrier ratio.
-
Aceclofenac Anglo French drugs and industries Pvt Limited
Lactose   SD Fine chemicals Ltd, Mumbai.
Micro crystalline cellulose   Loba chemie, Mumbai
Talc   Himedia Laboratories Pvt Ltd
Magnesium stearate           SD Fine chemicals Ltd, Mumbai.
Table.55 Equipments used for tablet formulation 
Name of equipment Name of company
Tablet punching machine Rimek Mini Press 1
Tablet disintegration test apparatus  Remi equipments 
Pfizer tablet hardness tester Scientific engineering corporation 
Roche friability tester Remi equipments
Dissolution apparatus Electoral TDT – 08L 
UV spectrometer Jasco V 530
pH testr 1 (water proof) Oakton instruments.
Method
The  required  amount  of  drug  and  the  other  additives  were  mixed 
thoroughly in a mortar and the tablets are prepared by direct compression using 
Rimek Mini Press 1 punching machine. The prepared tablets were stored in screw 
capped  glass  bottles.  The  prepared  tablets  were  evaluated  for  dissolution 
characteristics.
EVALUATION OF TABLETS: 51, 52.
The formulated  tablets  were subjected for the following quality control 
tests. 
• Weight variation 
• Disintegration test
• Friability
• Hardness
• Drug content uniformity
• Dissolution 
Weight variation test
Twenty tablets were taken weighed individually. They were evaluated for 
the weight variations. The weight variation allowed as IP limit is 5%. The weight 
of tablets with in the IP limits. The results were shown in table.56
Disintegration test 
The USP device to test disintegration uses six glass tubes that are three 
inches long open at the top and held against 10 inch screen at the basket rack 
assembly. A tablet is placed in each tube and the basket is positioned in a 1 liter 
beaker of distilled water at 37±2°C, such that the tablets below the surface of the 
liquid on their movement and descend not closer than 2.5 cm from the bottom of 
the tester. The disintegration time is 4 min.  45 sec. The results were shown in 
table.56
Friability test
Friability test was performed on the formulated tablets. The weight of the 
tablets after undergoing 100 revolutions was found to be within the limits 0.5 to 
1.0%. The results were shown in table.56
Hardness 
Pfizer hardness tester was used for measuring the hardness of formulated 
aceclofenac SD tablets. Five tablets wee taken randomly and subjected to test. The 
hardness was found to be 4-5 kg/cm2. The results were shown in table.56
Drug content uniformity
The prepared tablets containing aceclofenac solid dispersion was tested for 
drug content uniformity. Tablets were dissolved in 100 ml of pH 7.4 phosphate 
buffer  in  100ml  volumetric  flask  which  was  previously  clean  and  dry.  This 
solution after suitable dilution was measured for absorbance at 273 nm in a Jasco 
V530 UV visible spectrophotometer. The results were shown in table.56 
Table 56
Weight variation, disintegrating time, friability, hardness and drug content uniformity of tablets 
containing solid dispersions of aceclofenac
S. No.
Weight 
variation(%),weight 
range  of tablets(mg)
Disintegration 
time (sec)
Friability (%of 
loss of weight)
Hardness 
(kg/cm2)
Drug content 
uniformity(%)
1 571-578 620-655 0.8 4.9 -
2 531 241 0.5 4.4 94.5
3 547 248 0.6 4.5 92.4
4 542 256 0.56 4.2 93.6
5 512 243 0.50 4.4 90.6
6 553 249 0.57 4.6 94.5
7 531 248 0.71 4.2 95.4
8 538 284 0.63 4.3 99.3
9 542 250 0.52 4.1 93.0
10 551 251 0.64 4.8 97.2
11 578 259 0.7 4.0 99.0
12 537 253 0.6 4.3 92.4
13 533 257 0.52 4.7 100.2
14 529 264 0.55 4.6 94.5
15 539 265 0.4 4.2 92.4
16 548 261 0.72 4.3 93.6
17 537 249 0.50 4.8 94.5
18 541 285 0.61 4.9 99.0
19 552 264 0.67 4.6 97.4
20 547 258 0.5 4.3 92.5
21 535 267 0.66 4.5 96.2
In-vitro Dissolution studies
Dissolution  of  aceclofenac  from  various  tablets  was  studied  in  USP 
dissolution medium. The tablets containing solid dispersions equivalent to 100mg 
of aceclofenac were taken and the paddle type stirrer was adjusted to 75 rpm. The 
temperature  was  maintained  at  37±1°C.  5  ml  aliquot  dissolution  media  was 
withdrawn at different time intervals and volume withdrawn was replaced with 
fresh quantity of dissolution media. The samples were analyzed for aceclofenac 
by measuring absorbance at 273 nm using Jasco UV visible spectrometer. pH 7.4 
phosphate buffer was used as blank. The percentage of aceclofenac dissolved at 
various time intervals  was calculated and plotted against  time.  The results  are 
shown in table 57. and fig.44. 
Table  No.57 Dissolution  profile  of  aceclofenac  from  tablet 
formulation and from marketed tablets
Time in 
minutes
Percentage of aceclofenac released from
F1 F2 Marketed tablet
0 0 0 0
15 10.2 38.6 4.5
30 15.75 52.2 11.7
45 21.6 68.4 39.6
60 23.4 95.4 54.9
75 24.2 98.5 66.6
90 25.4 99.6 81.9
105 32.3 100.2 84.6
120 35.6 102.4 86.4
Figure 44 Dissolution profile of aceclofenac from tablet 
formulation and from marketed tablets
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RESULTS AND DISCUSSION
The results of drug content, hardness, friability test, disintegration test, are 
given in subsequent chapters. All the batches fulfill the official IP requirements 
for tablets. Hardness of the tablets in all the batches was found to be 4 to 5 kg/cm2 
and was satisfactory. The percentage weight loss in the friability test was found to 
be less than 1 % in all batches. Thus the tablets prepared were found to be good 
quality and fulfilling all the official requirements of compressed tablets.
The dissolution profile of various tablets formulated employing physical 
mixture  (F1),  aceclofenac-  PVP40  dispersions  (F2)  and  marketed  tablet  were 
shown  in  table  56.  Tablets  formulated  with  solid  dispersions  gave  rapid 
dissolution  of  the  medicament  when  compared  to  the  tablets  formulated 
employing  physical  mixture.  The  dissolution  of  medicament  from  all  tablets 
followed first order kinetics. The dissolution rate was found to be high in the case 
of  tablets  formulated  employing  solid  dispersions  indicating  rapid  and  higher 
dissolution of the medicament from these tablets when compared to the tablets 
formulated with physical mixture.
SUMMARY AND CONCLUSION
Studies  were  under  taken  on  the  preparation  and  evaluation  of  solid 
dispersions  of  aceclofenac  with  view  to  develop  fast  release  formulation  of 
aceclofenac. Four carriers viz PVP10, PVP40, PVP 360 and PVA 8136 were used 
to  prepare  the  solid  dispersions  of  aceclofenac  by  solvent  evaporation  and 
kneading method at various drug: carrier ratios namely (1:1, 1:3 and 1:9). The 
solid dispersions prepared were found to be fine and free flowing powders. X-ray 
diffraction studies revealed that crystalline nature of aceclofenac in pure form was 
reduced  to  amorphous  form  in  the  dispersions  The  thermal  behavior  of 
aceclofenac-PVP  40  solid  dispersion  was  studied  using  DSC  indicating  that 
aceclofenac  has  complexed  with  PVP  40.  This  phenomenon  is  indicative  of 
stronger interaction between aceclofenac and PVP 40 in the solid state. Interaction 
studies like TLC, FTIR indicated no interaction between drug and polymer used. 
Results  of  dissolution  studies  showed  rapid  and  fast  dissolution  of 
aceclofenac from all solid dispersions when compare with pure drug and physical 
mixture. Good correlation was absorbed between percentage carrier in the solid 
dispersion and T50 and T90 values. Among the four carriers PVP 360 gave highest 
dissolution rate in the drug carrier ratio of 1:9. 
The order of dissolution of aceclofenac from various carriers is 
PVP 360(KM)>PVP40 (KM)> PVP10 (KM)> PVP40, PVA 8136 (KM)> PVP10, 
PVA8136 (KM), PVP360 (SE)> PVP10 (SE)> PVP10, PVA 8136 (SE), PVP40, 
PVA 8136 (SE)> PVP360, PVA 8136 (KM)> PVP40 (SE)> PVP360, PVA 8136 
(SE)
Aceclofenac solid dispersion in PVP 40 (1:9) was formulated into tablets 
with  usual  additives  and  the  tablets  were  evaluated  for  dissolution 
characteristics .the dissolution of aceclofenac from tablet  formulation based on 
solid  dispersion  was  found  to  be  fast  and  rapid  when  compared  to  physical 
mixture of drug and marketed tablet.
The additives added have not hindered the dissolution of aceclofenac from 
solid dispersions. All the tablet formulations based on the solid dispersion fulfilled 
the official dissolution requirements. Hence the tablet formulations based on solid 
dispersions are considered as fast release dosage of aceclofenac.   
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